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Abstract 
 
The establishment and long-term maintenance of virus-specific memory CD8+ cytotoxic T 
lymphocytes (CTL) is genetically controlled. However, not all genes involved in this process 
have been identified in vivo to date and their identity and function have to be clarified. To 
identify novel genes which regulate the development of memory cells, we have undertaken 
an in vivo forward genetic approach based on germline mutagenesis screening. Random 
point mutations were introduced in the genome of wild-type mice by N-ethyl-N-nitrosourea 
(ENU) treatment. A library of third generation mutants was then screened for genetic 
defects affecting their immune responses to Lymphocytic Choriomeningitis virus (LCMV).  
 
Altered immune responses to LCMV in mutant mice were detected by measuring the 
percentage of antigen-specific CTL, their cell death and the composition of the LCMV-
specific CD8+ T cell pool at the peak of expansion and at the beginning of the memory phase. 
Any individuals with outstanding cell population numbers or characteristics were isolated as 
phenodeviants. Once a mutation was confirmed to affect the germline, a stable strain was 
established and the mutation was mapped by positional cloning. Through this process, we 
have isolated 3 mutants: memi, binu and alois.  
 
Our first mutant, memi was isolated based on its very low CD8+ T cell memory population 
following LCMV infections. Using single nucleotide polymorphism linkage analysis, we 
identified memi as a loss-of-function mutation in the gene encoding deoxycytidine kinase 
(dCK), a crucial enzyme of the nucleoside salvage pathway. In addition to the immunological 
phenotype observed after viral infection, we have characterized significant changes in T and 
B lymphocyte development and their cell-intrinsic/extrinsic peripheral homeostasis in naive 
memi mice. This mutant is valuable especially to understand how a defect in nucleoside 
salvage impacts on lymphocyte development and behaviour.  
 
The other two mutants, binu and alois, which present increased and decreased CD8+ T 
memory precursors upon LCMV infection, respectively, are currently being mapped. To our 
12 
 
knowledge, no mutant with exactly the same phenotypes as binu or alois has been 
described to date and we therefore believe that they have strong potential to be novel 
mutants.  
 
Overall, our ENU mutagenesis was successful both in terms of the number of mutants we 
have isolated and the types of mutations they represent, affecting known and potential new 
immune regulators. 
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Introduction 
 
1. Innate and adaptive immunity 
Upon an invasion by foreign pathogens, the innate arm of the immune system is the first line 
of host defence while the adaptive immunity gets activated. Since the innate immune 
response does not require the recognition of specific antigens or clonal expansion of 
immune cells, it generates immediate responses to infectious pathogens. In contrast, the 
initiation of adaptive immune responses is a more complex and time-consuming process, as 
it involves antigen-presentation, recognition and subsequent clonal burst of activated 
lymphocytes. However, it provides more specialized and powerful means of pathogen 
removal, and produces memory cells which will react highly efficiently upon a second 
infection with the same pathogen.  
 
1.1 Innate immunity  
When infectious pathogens invade host tissues, they are recognised by resident immune 
cells in the tissue which will attack them directly and activate the adaptive immunity 
(reviewed in Medzhitov and Janeway, 2000 (Medzhitov and Janeway, 2000)). One type of 
these innate immune cells is macrophages which will notably recruit neutrophils to 
phagocytose and kill pathogens by several mechanisms such as acidification of phagosome 
and production of toxic nitrogen oxides and reactive oxygen species. For the antigen 
recognition, phagocytes rely on pattern-recognition molecules such as macrophage 
mannose receptors and scavenger receptors, in addition to Toll-like receptors (TLR) such as 
TLR-4 and TLR-2. TLRs are highly specified antigen recognising surface molecules which 
trigger the expression of NFKB to induce the production of inflammatory cytokines such as 
TNFα, IL-1, and IL-6 (reviewed in Schnare et al. (Schnare et al., 2006)). These cytokines 
facilitate the expression of leukocyte adhesion molecules such as selectins, integrins, and 
immunoglobulin superfamilies (ICAM). In addition, IL-12 which is produced by macrophages 
can induce the development of Th1 cells and activate NK cells (Watford et al., 2003). NK cells, 
which are also stimulated by type I interferons (IFNα and IFNβ) produced by cells in response 
to microbial and viral infection, induce apoptosis of infected host cells, produce antiviral 
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IFNγ to inhibit viral replication directly and mediate antigen-specific CD8+ T cell responses 
(Biron and Brossay, 2001). Meanwhile, antigen-presenting cells (APC) uptake the pathogen 
and migrate to secondary lymphoid organs where they will activate naïve lymphocytes to 
induce adaptive immunity.  
 
1.2 Adaptive immunity 
Innate immunity is very efficient in removing pathogens. However, microbes and virus have 
developed their own evasion mechanisms to overcome these innate defences. In this case, 
the adaptive arm of the immune system provides a better protection to the host organisms. 
The key players of the adaptive immunity are T and B lymphocytes that are activated by 
antigen-presenting macrophages and dendritic cells (DC). First, DC present at the site of 
infection will uptake pathogens, degrade them into peptides which they will present on their 
surface MHC molecules. This will correlate with the migration of DCs to secondary lymphoid 
organs where naive lymphocytes reside and will get subsequently activated. While T cells 
can mediate cytotoxic killing of infected cells, B cells produce antibodies which can opsonise 
and neutralise invaded pathogens. Naive T lymphocytes require three signals to be fully 
activated. First, their T cell receptors (TCR) have to recognise specific peptide-MHC complex 
on DC. Peptides presented by MHC class I molecules are recognised by TCR on naive CD8+ T 
cells while TCR on CD4+ T cells recognise peptides presented on MHC class II molecules. 
Second, the signal from the TCR has to be "confirmed" by signals from co-stimulatory 
molecule binding, such as binding of CD28 on T cells to CD80 or CD86 on DC (June et al., 
1987). This secondary signal prevents unnecessary activation of naive T cells by self peptide-
MHC complex recognition. Finally, inflammatory and antiviral cytokines produced by 
macrophages and neutrophils also enhance the activation of naive T cells (signal 3).  
Upon intracellular viral infection, naïve CD4+ T cells differentiate into Th1 cells which help 
the removal of viral particles by macrophages and produce IFNγ and IL-2 (Colavita et al., 
2000). Activation and behaviour of CD8+ T cells are explained below. On the other hand, 
excessive IL-4 produced by NK T cells upon presence of extracellular antigens such as gram-
negative bacterial lipopolisaccharides (LPS) or allergens such as ovalbumin (OVA) can induce 
CD4+T cells to become Th2 cells. They activate B cells to induce the humoral immune 
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response and secrete anti-inflammatory cytokines such as IL-4, IL-10 and TGFβ.  
 
1.3 CD8+ T responses and memory formation upon acute viral infection  
Upon acute viral infection, DC presenting viral peptide-MHC class I molecule complexes 
migrate to secondary lymphoid organs where naive CD8+ T cells reside. Viral peptide-MHC 
molecules on mature DC are recognised by naive CD8+ T cells, and together with the co-
stimulatory molecules and cytokines, CD8+ T cells develop into cytotoxic T lymphocytes (CTL) 
and undergo a phase of massive proliferation (clonal expansion) (fig. 1).  
 
%
A
g-
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TL
Time
Activation
Expansion
Contraction
Memory
Recall 
response
Primary infection Secondary infection
 
Figure 1: Schematic representation of the antigen specific CD8+ T cell response against 
acute viral infections 
Blue arrows indicate viral infections, the red line the Ag-CTL population of cells.  
 
CTL express Fas-ligands and produce perforin and granzymes to induce the apoptosis of 
infected cells. They also produce IFNγ and TNFα to enhance their own activity (Klavinskis et 
al., 1989; Kristensen et al., 2004). Once viral pathogens are cleared from the host, most of 
the antigen-primed T cells are removed by apoptosis as they are no longer needed 
(contraction). However, some of them evade apoptosis to develop into functional memory 
cells. Their long-term homeostatic self-renewal is maintained by IL-7 and IL-15 (Wherry and 
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Ahmed, 2004) produced by epithelial cells and monocytes in lymphopoietic tissues. 
Especially, IL-7 is important for memory T cell survival, therefore, the re-expression of IL-7 
receptor (IL-7R) on antigen-primed CD8+ T cells is considered as a hallmark of memory cell 
development (Kaech et al., 2003).  
These memory T cells retain the potential to respond more effectively and more rapidly to a 
second exposure with the same pathogen (recall response) (Bachmann et al., 1999). 
Depending on their surface marker expression, memory T cells can be divided into two 
subsets: central memory cells (Tcm; CD62L+CCR7+) and effector memory cells (Tem; CD62L-
CCR7-). During the recall response, Tem present immediate effector-like phenotype while 
Tcm directly supply effector cells.  
 
Inducing effective CD8+ memory T cell responses has been a prime concern for vaccination 
that aim to protect the host from infections. A better knowledge of the regulators of 
memory CD8+ T cells will eventually contribute to the development of vaccines and 
adjuvants which induce long lasting immune responses to intracellular pathogens. 
 
1.4 Known genes controlling CD8+ T cell memory formation 
To become a memory cell, a naive CD8+ T cell has to be stimulated by a DC presenting its 
cognate antigen, has to escape cell death and has to enter quiescence to prevent replicative 
senescence which is caused by telomerase-independent factors such as activation of tumor 
suppressor genes, in case of rodents (Itahana et al., 2004). These events are genetically 
controlled as deficiencies in specific genes will alter the course of memory formation. For 
example, Spi2A (Liu et al., 2004b) and Bcl-2 (Wojciechowski et al., 2007) protect cells from 
programmed cell death (PCD) while cathepsin B (Liu et al., 2004b) and Bim (Sabbagh et al., 
2006) induce extensive cell death during the contraction phase. In addition, DNA microarray 
analysis have shown that genes such as TGFβ, Sno-A, Ski, Myc are up-regulated in quiescent 
CD8+ T cells (Zhang et al., 2008). Genes which are known to regulate CD8+ T cell expansion-
contraction and memory formation are listed in the table below (Table 1).  
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GENE Function REFERENCE 
BIM Required for the contraction of CTL and represses CD8
+ T cell 
memory precursor formation  
(Wojciechowski et 
al., 2006a) 
T-bet 
Induces effector cell development 
Low expression levels in IL-7Rαhi memory precursor cells upon 
infections  
Induces Tem formation  
(Intlekofer et al., 
2007) 
GABPα 
Required to maintain a higher expression of IL-7Rα in memory 
T cell precursors 
(Chandele et al., 
2008) 
GFI1 Required to repress IL-7Rα transcription in CTL  (Chandele et al., 2008) 
Bcl-2 Enhances the survival and generation of memory CD8
+ T cells 
Favours Tcm formation (Ichii et al., 2004) 
Blimp-1 
Enhances CTL function and proliferation  
Inhibits memory development  
Induces Tem formation  
(Rutishauser et al., 
2009) 
Spi2A Protects CTL from apoptosis during the contraction phase (Liu et al., 2004a) 
Spi6 Protects CTL from apoptosis during the expansion phase (Zhang et al., 2006) 
Perforin Inhibits CTL expansion and persistence (Kagi et al., 1999) 
DOCK8 Required for memory T cell survival (Lambe et al., 2011) 
IL-7Rα Required for memory T cell survival  (Kaech et al., 2003) 
Puma Induces apoptosis of CTL during the contraction phase (Fischer et al., 2008) 
Id2 Protects CTL from apoptosis during the expansion phase (Cannarile et al., 2006) 
Table 1: Genes controlling antigen-specific CD8+ T cell expansion-contraction and 
memory formation  
 
However, not all of the regulators of CD8+ T memory are known to date as for example we 
do not yet know how the size of the functional CD8+ T memory pool is determined upon 
infections: IL-7Rα expression is known to be crucial for memory CD8+ T cell survival (Kaech et 
al., 2003), however, overexpression of IL-7Rα did not increase the size of CD8+ T memory 
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pool as it alone could not protect cells from apoptosis (Haring et al., 2008; Sun et al., 2006). 
To fully understand how CD8+ T cell memory is generated and maintained in the host for 
long periods of time, more genes involved in this process have to be investigated. In  
particular, we are interested in genes which protect cells from apoptosis and lead them to 
quiescence to become long-term memory cells. To achieve this, we designed a mutagenesis 
project based on forward genetic approaches.  
 
2. Forward genetics 
Two main approaches can be used to discover gene identity and function. The first one, 
reverse genetics, relies on the disruption of genes of interest. Candidate genes may be 
selected based on results from DNA microarrays (Liu et al., 2004b) or because they belong to 
a certain family of genes of interest (Alexopoulou et al., 2001). The analysis of the mutant 
phenotype subsequently informs on the gene function (Rutschmann and Hoebe, 2008). 
Reverse genetics is a relatively rapid strategy to understand a gene function because the 
identity of the gene is known from the beginning. However, this hypothesis driven strategy 
has some disadvantages : 1. The complete disruption of genes required for development can 
be lethal, preventing the analysis of adult animals (Baker et al., 2005), 2. Even though the 
gene might be a good theoretical candidate (based on expression pattern or belonging to a 
specific family of genes), it might not be involved in the specific phenomenon of interest, 
resulting in the absence of phenotype, 3. Genetic redundancy might occur and result in the 
absence of phenotype in the mutant mouse (Hager et al., 2009), 4. The mixed genetic 
background in which some mutant mice are generated might affect the phenotype, 
independently of the mutation (Rutschmann and Hoebe, 2008).  
 
By contrast, the second one, forward genetics, is not based on any functional hypothesis 
(Beutler et al., 2006) and has therefore a high potential to discover new genes and new 
functions of known genes. It starts from a mutant phenotype and goes back to the genotype 
to find out the responsible affected gene (Beutler et al., 2007). Forward genetics can consist 
in the analysis of existing strain differences (Poltorak et al., 1998), in the study of naturally-
occurring mutations (Hosoda et al., 1994) or in the screening of randomly generated 
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germline mutations (Crozat et al., 2006; Randall et al., 2009). In the case of random germline 
mutagenesis, if a mutation induces the aberrant translation of a protein, the particular 
function of its altered domain can be studied further and it would be therefore be beneficial 
to understand the functional importance of this particular domain. In addition, by using a 
forward genetic approach, it is possible to discover novel genes that control particular 
pahenotype. This later approach is the one we chose for this project. 
 
3. N-ethyl-N-nitrosourea (ENU) germline mutagenesis 
The steps of a germline mutagenesis are depicted in figure 2. 
 
Mutagenesis 
Breeding 
Screening 
Confirmation of the 
mutation transmissibility 
Genotyping and 
Phenotyping
Isolation of phenotype 
of interest
Establishing the 
mutant strain 
 
Figure 2: Steps of a germline mutagenesis 
 
First, mice are mutagenised with ENU which will induce random DNA changes in their 
germline cells. Subsequent breeding allows the generation of a library of unique mutant 
mice. These animals are then individually screened to isolate mutants specifically affecting 
the phenomenon of interest (phenodeviants). Once the transmissibility of the mutation in 
the germline is confirmed, the mutant strains are established and they are analysed to 
identify the affected gene (mapping/genotyping) and to understand its function 
(phenotyping). Each of these steps is described in more details below. 
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3.1 Mutagenesis 
For our study, random mutations were generated by using a chemical mutagen, ENU (fig. 3). 
ENU induces the highest mutation rate in the mouse (Justice et al., 2000a), with up to 1 
change per million base pairs of genomic DNA, depending on the administrated dose 
(Concepcion et al., 2004). ENU preferentially affects pre-meiotic spermatogonial stem cells 
(Balling, 2001) in which it creates random point mutation by transferring its ethyl group to 
DNA base pairs (Concepcion et al., 2004). This will predominantly affect A-T base pairs rather 
than G-C pairs (Acevedo-Arozena et al., 2008). Since ENU is toxic and likely to induce 
depletion of multiple stem cell types such as haematopoietic stem cells, mice injected with 
ENU are temporally sensitive to pathogens therefore, their survival rate is affected. In 
addition, their germ cells, especially spermatogonial cells are depleted by the ENU toxicity, 
they undergo a sterile period (Weber et al., 2000).  
 
 
Figure 3: ENU structural formula 
The ethyl group which is transferred to DNA base pairs is high lightened by the red square.  
  
Generally, to perform a mutagenesis, one single dose or fractional doses of ENU is/are 
injected into animals and after they recover fertility, they are bread to obtain mutant 
offsprings.  
 
Our mutagenesis was performed in the C57BL/6J inbred strain for the following reasons:  
 
1/ C57BL/6J was the inbred strain of choice used for the mouse genome sequencing project 
2/ The CD8+ T cell immune response of C57BL/6J animals to the virus we have used in our 
screen has been very well described in is highly reproducible 
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3/ C57BL/6J males re-gain their fertility after the final ENU injection and can tolerate toxicity 
of ENU relatively well (Justice et al., 2000a; Weber et al., 2000) 
4/ There are several published studies that successfully generated mutants with C57BL/6J by 
ENU germline mutagenesis (Beutler et al., 2006; Concepcion et al., 2004; Crozat et al., 2006; 
Randall et al., 2009; Rutschmann et al., 2006). 
 
3.2 Breeding  
The mutagenesis is usually followed by up to three generations of breeding, allowing the 
recovery of mutant mice heterozygote or homozygote for the generated germline mutations. 
Depending on the screening objectives, several breeding schemes can be used. In all of the 
descriptions below, G0 refers to the ENU injected animals, G1 to the first generation of pups, 
G2 to the second, etc.. 
 
1/ Breeding scheme to screen for heterozygous dominant mutations: When ENU-injected 
males recover their fertility, they are bred to wild type females to produce G1 mice. Since 
the wild type females will not, in theory, carry any mutation, G1 mice can only be 
heterozygous for the ENU-induced mutations. If one of those is dominant, it will reveal itself 
in G1 heterozygotes.  
 
2/ Breeding schemes to screen for homozygous recessive mutations: It takes a minimum of 3 
generations to isolate a mutation as a homozygous trait. Two main breeding schemes are 
generally used. G1 males, produced as described above, are mated with wild type females to 
produce G2 mice. These G2 mice can either be intercrossed (brother/sister mating) or 
backcrossed with their father to obtain G3 mice. In the case of backcross, if the mutation 
exists, we are certain that the G1 mouse is heterozygous for the mutation. The G2 female 
can either be heterozygous or wild type, therefore, there is 50% chance that this G1 x G2 
pair is Het x Het. On the other hand, in the case of intercross, the possibility of G2 male to 
be heterozygous for the mutation is 50% and the possibility of G2 female to be heterozygous 
is 50%, therefore, the possibility of both G2 animals are heterozygous is 25%. Because of this 
reason, theoretically, intercross breeding scheme requires more G2 x G2 breeding pairs to 
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efficiently isolate mutants.  
 
Our chosen breeding scheme to isolate homozygous recessive mutations is a backcross 
scheme and was set up as follows (fig. 4).  
 
 
Figure 4: Germline mutagenesis and breeding scheme to isolate homozygous recessive 
mutations 
ENU injected G0 wild type males are mated to wild type C57BL/6J females to produce the 
G1 offspring. To isolate homozygous recessive mutations, these G1 males are bred with wild 
type females and two G2 females are backcrossed with their G1 fathers to produce a G3 
progeny. The G3 females were screened for phenotypes of interest. The red arrow indicates 
the ENU injection. 
 
G0 males were bred to wild type females to obtain G1 males. When G0 males are injected 
with a 100mg ENU/kg body weight, it is estimated that they carry around 33 heterozygous 
coding changes in their genome (Concepcion et al., 2004). G1 males were then crossed with 
wild type females and two of their G2 daughters backcrossed to the G1 father to obtain the 
G3 progeny. Each of these G3 animals is thought to carry approximately 3 to 4 homozygous 
coding mutations (Concepcion et al., 2004). This breeding scheme automatically excluded 
any possibility of isolating sex chromosome-linked mutation as only the Y chromosome of 
ENU-injected males is inherited by G1 males and we screened G3 females which only carried 
WT
WT
Females for 
screening 
phenodeviants
C57BL/6J
ENU
G0
G1
G2
G3
males
females
heterozygous
homozygous
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X chromosomes to reduce variations in our screening parameters. 
 
Based on the work from other laboratories (Concepcion et al., 2004), our ENU dose and our 
backcross breeding scheme, we could expect that the probability of isolating a particular 
mutation present in the G1 in at least one G3 mouse is approximately 50% when two G2 are 
backcrossed and three G3 screened per G2. This probability can be explained in details:  
 
1/ When both the G1 and G2 are heterozygous for a given mutation, the probability of 
having 1 homozygous G3 out of m number of G3 tested is 1-(3/4)m. For example, if 3 G3 are 
screened per G2 mother, this probability is [1-(3/4)3]x100=57.8%.  
 
2/ However, there is a certain probability that the G2 mother is not heterozygote for the 
particular mutation. The probability of a G2 female to be heterozygote is 50%. Therefore, the 
probability for a particular mutation to be homozygous in one G3 mouse will be: 1/2x(1-
(3/4)m). For example, the probability of a G1 mutation being homozygous in one of the three 
G3 from a single G2 mother is 1/2x[1-(3/4)3]x100= 28.9%. 
 
3/ If n G2 females are backcrossed to their G1 father, the probability of having at least one 
homozygous individual in the three G3 per G2 mothers is obtained by the equation {1-1/2[1-
(3/4)m]}n which simplifies as p=1-[1/2+1/2(3/4)m]n (Concepcion et al., 2004). For example, if 
m G3=3 and nG2=2, this probability is approximately 50%. If 6 G3 were tested per G2 mother, 
this probability would only increase to 65% but would double our screening work, thus 
considerably reducing our efficiency. Testing 3 G3 from 2 G2 mother per G1 male is therefore 
a good compromise between isolating mutations and the screening efficiency. 
 
3.3 Screening and isolating phenodeviants affecting CD8+ T cell immune responses 
Our goal was to isolate mutations affecting regulators ofCD8+ T cell memory formation and 
maintenance in response to viral infections. To induce an immune response leading to the 
formation of antigen-specific memory, we decided to use Lymphocytic Chriomenigitis virus 
(LCMV) for our screen. This virus is a natural pathogen for mice and leads to the activation of 
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the immune system (Ahmed et al., 1984).  
 
3.3.1 LCMV Armstrong  
LCMV belongs to the arenaviridae family of virus which also includes Lasa, Sabia, Guanarito, 
Junin, and Machupo virus. They all mainly infect rodents but also transmit diseases to 
humans causing symptoms like aseptic meningitis and haemorrhagic fevers (Oldstone et al., 
1985). LCMV is enveloped in a lipid membrane with viral glycoprotein spikes and projections 
(Neuman et al., 2005) (fig. 5). The viral genome contains a large (L) and a small (S) RNA 
segment which encode viral proteins (Oldstone et al., 1995). Known strains of LCMV, such as 
LCMV WE, Docile, Armstrong, Armstrong Clone 13, Traub and Aggressive are reported to 
induce different immune responses in C57BL/6J mice (Moskophidis et al., 1994). LCMV 
Armstrong is commonly used to induce acute infection C57BL/6J mice.  
 
 
Figure 5: lymphocytic choriomeningitis virus 
Viral envelope spikes and projections are indicated by white arrows. bar=500Ȧ (obtained 
from Neuman et al, 2005) 
 
3.3.2 C57BL/6J CD8+ T cell immune responses to LCMV Armstrong infection  
When wild type C57BL/6J mice are infected with LCMV Armstrong, their antigen-specific CTL 
(Ag-CTL) population rapidly expands to reach a peak at day 8 post infection, undergoes 2 
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weeks of contraction and around day 21, they enter quiescence to become memory cells (fig. 
6) (Opferman et al., 1999). 
 
 
 
Figure 6: LCMV-specific CTL behaviour upon LCMV Armstrong infection in 
C57BL/6J mice (upper) and expected types of mutants (lower) 
The red line indicates the theoretical wild type Ag-CTL response to LCMV infection at day 8 
and day 21. Four main types of mutants are expected according to G3 mice's immune 
response to LCMV. Some mutants will affect the expansion phase (the blue and green lines) 
and some only the contraction phase (the orange and gray lines). The arrow indicates LCMV 
infection.  
 
Several categories of mutants changing this pattern can be expected: mutants with 
increased (hyper-expansion) or decreased (hypo-expansion) numbers of Ag-CTL at day 8, and 
mutants with increased (hypo-contraction) or decreased (hyper-contraction) numbers of Ag-
CTL at day 21 compared to wild type animals (fig. 6). Known mutants exemplify these 
phenotypes: Spi6 for hypo-expansion (Zhang et al., 2006), Perforin for hyper-expansion 
mutant (Kagi et al., 1999), TNFR-associated factor (TRAF)-1 for hypo-contraction (Sabbagh et 
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al., 2006) Spi2A for hyper-contraction (Liu et al., 2004a).  
 
Our screen was aiming to specifically address two questions: 
- What are the protective factors that prevent death of memory precursors  
- What are the genes inducing quiescence in these memory precursors 
 
To isolate mutation in protective factors, we decided to measure the amount of antigen 
specific CTL in infected mice at the peak of the expansion and the end of the contraction. 
Our reasoning was that a mutation affecting such a protective factor would either increase 
or decrease the level of contraction between these two time points. The measure was done 
by using a H-2Db MHC class I tetramer which specifically recognize LCMV glycoprotein gp33-
41 antigen peptide (gp33) on CTL presented on MHC allele H-2Db of B6 mice. Gp33-41 and 
np396-401 are the two major viral epitopes driving CTL expansion in mice (van der Most et 
al., 1998). We also included Yopro-1, a DNA intercalating dye (Idziorek et al., 1995), as one 
screening parameter to measure the level of apoptotic CTL.  
To isolate mutations affecting quiescence regulators, we decided to measure the population 
of slowly proliferating CTL at the end of contraction by BrdU pulse-chase experiment 
(explained in details in the result section). Our reasoning was that any mutation affecting a 
quiescence inducer would result in a change in the distribution of BrdU incorporating cells 
after the contraction phase.  
 
3.3 Isolation of phenodeviants 
To isolate phenodeviants efficiently and to minimize isolating false positives, screening 
parameters had to be tightly controlled.  
First, a reliable wild type standard for each screening parameter was required. Since ENU, 
without generating specific mutations of interest, might have affected the general genetic 
background of our G3 mice, their responses to LCMV might not be the same to that of pure 
wild type mice. Therefore, the immune responses of wild type and G3 mice had to be 
compared.  
Second, we needed to define the cut off values which would allow us to distinguish mutants 
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from wild type animals. A mutant, by definition, means an individual which has a 
distinctively different trait than the average population. We can define an average trait by 
calculating the mean value of the trait. To determine how different an individual is from the 
mean, we used the standard deviation value (SD). SD indicates the degree of distribution of 
measured data from the mean value. In other words, a great SD value means that the 
measured individual data are sparsely distributed from the mean value, and a small SD value 
indicates that the individual data are closely located to the mean value. When the 
population of individuals follows a Guassian distribution, 68% of this population lies within 1 
SD on each side of the mean and 95% within 2SD from the mean. Therefore, if we use mean 
± 1 SD for the cut off value, in theory, we might end up isolating 3 phenodeviants every 10 
screened G3 mice. However, when compared to previously reported rates of confirmed 
mutants per screened mice, this value is far too high. We therefore decided to set our cut off 
values at mean ± 2 SD: any mouse within this range was considered wild type and mice 
presenting values outside of this range considered phenodeviant. Finally, to reduce any 
additional variations, we decided to use 6 weeks old apparently healthy G3 female mice only 
for the screen.  
 
3.4 Confirmation of the transmissibility of the mutations in the germline (retests) and 
creation of stable mutant strains 
 
3.4.1 Somatic versus germline mutations 
Once phenodeviants were isolated, the transmissibility of the potential mutation in the 
germline had to be confirmed. To do so, we tested at least 6 additional siblings (retests) from 
the same parents than the original mutant individual. The mutation was considered 
transmissible in the germline if the same original phenotype was found in the additional 
tested sibling. If we could not find a single mouse with the same phenotype as the original 
phenodeviant, we considered that the original phenodeviant was either a false positive 
produced by experimental error, or that the mutation was affecting somatic cells (for 
example a CTL precursor) and was therefore not transmissible in the pedigree.  
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3.4.2 Dominant versus recessive mutations 
Once the transmissibility of the mutation in the germline was confirmed, the next step was 
to establish a stable mutant strain. We first needed to define the mode of inheritance of the 
mutation: for example recessive, dominant or co-dominant. To do so, we relied on the 
principles described by Mendel to explain genetic inheritance. In short, the laws of 
Mendelian inheritance describe how traits are passed onto lower generations. In our case, 
we could rely on the fact that the obtention of a mutant G3 mouse meant that the G1 father 
must be heterozygous for the mutation whereas the G2 mother could be either 
heterozygous or wild type for the mutation. Consequently, the following scenarios are 
possible:  
 
1/ G1 (Het) x G2 (WT) (table 2): if the G2 mother is wild type for the mutation, then the 
expected genotypes of the offsprings are either heterozygous (50%) or wild type (50%). Only 
dominant or co-dominant mutations can therefore be isolated in the G3 population. The 
Mendelian expected mutant ratio for a dominant mutation in the G3 population is therefore 
50%.  
 
    M(G1) 
F(WT) 
+ - 
+ +/+ +/- 
+ +/+ +/- 
Table 2: Possible genotypes of G3 mice obtained from a G1 (Het) x G2 (WT) pair 
M = male, F = female, + = wild type allele, - = mutant allele. 
 
2/ G1 (Het) x G2 (Het) (table 3): When the G2 mother is heterozygous for the mutation, then 
the expected genotypes for their offspring are wild type (25%), heterozygous (50%) and 
homozygous (25%). In this case, a dominant mutation would be observed in 75% of the 
offspring and a recessive mutation in 25% of them. If the mutation is co-dominant, then the 
"intermediate" mutant phenotype will be detected in 50% of the litter, the wild type in 25% 
and the “complete” mutant phenotype in the remaining 25%. 
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     M(G1) 
F(G2) 
+ - 
+ +/+ +/- 
- +/- -/- 
Table 3: Possible genotypes of G3 mice obtained from G1 (Het) x G2 (Het) pair 
M = male, F = female, + = wild type allele, - = mutant allele. 
 
3.4.3 Other parameters to consider during the retests: 
 
1/ Penetrance: The penetrance of a mutation is defined by the proportion of individuals 
carrying a mutant gene and presenting an associated phenotype. The degree of penetrance 
can be measured by relating the expression of the phenotype with the presence of mutant 
allele in the gene (Bassett et al., 1998). If a mutation has a high penetrance, then the 
mutation will be expressed in most animals carrying the mutated allele. Depending on the 
penetrance of the mutation, the ratio of having mutant individuals in the retests could vary. 
Mutations with low or incomplete penetrance would be difficult to work on, because 1/ 
their traits are less likely to be expressed even though individuals are carrying the mutated 
allele and 2/ the inheritance of the mutant allele is low therefore it is not ideal to 
establishing mutant strains and map the mutation. Therefore, we aimed to only consider 
mutants with high or complete penetrance, relying on Mendelian mode of genetic 
inheritance.  
 
2/ Lethality: Some dominant and recessive mutations are known to be embryonic lethal. For 
example, lethal yellow (Ay) is a well-known homozygous lethal gene which causes embryonic 
lethality in mice (Michaud et al., 1993). However, heterozygote Ay mice are born normally, 
but have an agouti coat colour. Therefore, when two agouti mice are bred, the expected 
ratios in their offspring is 2/3 Ay/+ and 1/3 for wt +/+.  
 
By taking into account all these parameters, we compared our obtained mutant ratio to 
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theoretical ratios in order to predict how the mutation is inherited.  
 
3.4.4 Establishing mutant strains 
Because our screening relies on an infection with LCMV, a Containment Level (CL) 3 
pathogen in the UK, the whole screening procedure was performed in a CL3 environment. 
Once mice are transferred to a CL3 procedure room, they are not allowed to come back to 
the normal breeding and stock room and therefore cannot be used for breeding. To establish 
stable mutant strains, we had to randomly intercross non-infected G3 siblings of the isolated 
mutant, test their G4 progeny with LCMV to establish the ratios of inheritance. This allowed 
us to back-track the G3 parental genotypes of each individual G3 intercross pair and 
establish further breeding cages until we had homozygous breeding pairs. In theory, 16 
cages of G3 intercross are necessary to have at least 1 homozygous breeding G3 x G3 pair 
when starting with heterozygous parents (G1 x G2 for example). However, when an isolated 
mutant also presented phenotypes which can be distinguished without LCMV infection, 
homozygous breeding pairs were established based on the non-immune phenotype (for 
example memi, see results).  
 
3.5 Genotyping and phenotyping 
To identify the gene affected by a mutation, we used a positional cloning by linkage analysis 
approach. This is done by using a panel of markers (either SNP or microsatellites) which are 
spread over the genome. The exact location of these markers is known in relation to the 
published mouse genome sequence (Ensembl). The approach relies on recording meiotic 
recombination events between the markers and the mutation and subsequently calculating 
the probability of each particular marker to be associated with the mutation by chance or 
because they are physically linked. This probability is called the Logarithm of Odd (LOD) 
score. 
 
Depending on the type of mutation, several breeding strategies for mapping can be adopted. 
As all three mutants presented in the rest of this thesis are purely recessive, the mapping of 
dominant mutations will not be covered here.  
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3.5.1 Breeding strategy for genotyping a recessive mutation 
The first step consists in out-crossing the mutant mouse (C57BL6/J background) to a wild 
type mouse with a different inbred genetic background (for example 129SvImJ). This second 
inbred strain carries different alleles for the chosen markers than C57BL/6J. This breeding 
generates first generation hybrid mice (H1) which are heterozygous for all the markers and 
the mutation and in which germline cells meiotic recombination will take place. Two 
breeding strategies can subsequently be adopted: backcross to the mutant strain or 
intercross of H1 animals to obtain second generation hybrids (H2) (fig. 7). These H2 mice are 
subsequently analysed for their phenotype and the genotype of all the chosen markers. 
Generally, the backcross strategy is used when the phenotypic difference between the 
mutant and wild type is not great or when the mutation is inherited in a co-dominant 
manner. On the other hand, when H1 intercross is performed, we can get more genetic 
information per H2 mouse as each of them will have twice as many meiotic recombination 
events as H2 mice produced by backcross. Therefore, when they are analysed, three 
genotypes can be found, in our case, one from C57BL/6J, one as a hybrid 
C57BL/6J//129SvImJ, and the other one from strain 129SvImJ, while in the case of backcross, 
only two genotypes (one from C57BL/6J and the other one as a hybrid C57BL/6J//129SvImJ) 
exist at each locus of H2 animals.  
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Figure 7: Breeding schemes for whole genome mapping of recessive mutations 
The upper panel describes a backcross breeding scheme and the lower panel an intercross 
breeding scheme for whole genome mapping.  
 
3.5.2 Linkage calculation 
The genotyping and phenotyping of individual H2 animals allowed us to calculate the 
probability of particular markers spread over the genome to be associated with the 
mutation by chance or because they are physically linked. This logarithm of odds (LOD) score 
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was, first developed by Newton E Morton.  
 
In as simple way, the concept of the equation for calculating a LOD score [Z(φ)] is described 
as follows:  
 [Z(φ)] = Log ????????????????????????? ???????????????? ????????????????????????????????????????? ???????????????? ???????????????????? 
 
To calculate the probability that the mutation and a marker A are linked or not, the existence 
of the mutation and the marker A in a same individual has to be acquired. This is done by 
sequencing for the marker and phenotyping the individual mouse. If none of the mutants is 
carrying the marker A, then the marker is considered to have no linkage with the mutant 
gene. In this case, the loci for the marker and the mutation are either far apart on the same 
chromosome or on different chromosomes. Since the linkage analysis is performed on two 
loci on the same chromosome, we will not consider the latter case. During meiosis, if two 
loci are not linked, 50% of the gametes will be of parental type and the other 50% will be of 
non-parental (recombinant) type. From this, the recombinant fraction of two non-linked loci 
is obtained as 0.5 (50%). Therefore, when none of n mutant animals carries the marker A, 
the probability that the mutation and the marker are not linked is obtained by 0.5n.  
 
In contrast, when the loci for the mutation and the marker A are close enough so that 
sometimes they do not get separated by the recombination event, they are considered to be 
linked. The closer they are, the smaller the chance that recombination takes place between 
them. When the chance of recombination takes place between the two loci is φ i.e., the 
probability of having a recombinant type of gamete is φ, the probability of having a parental 
type is (1- φ). When k number of animals out of n number of mutant animals have the 
recombinant type, n-k number of animals are considered to have the parental type. 
Therefore, the probability that the mutation and the marker are linked is obtained by φk x (1-
φ)n-k. Finally, the equation for LOD score is summarised as follows:  
 [Z(φ)] = Log ???????????????  
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The LOD score defines a region of interest which contains the mutation. This region is 
located between the two or three markers giving the highest LOD score. A LOD score of 5 
means that the possibility that the mutation does NOT lie in this specific region is 1 in 105.  
 
Depending on the size of the region of interest and its complexity, three options are 
available to find the affected gene:  
 
1/ Fine mapping of the region: the affected gene can be localized by fine mapping using 
other markers which are distributed in the region. This may be useful when the defined 
region is still too large or has a high density in genes. Subsequently, a LOD score will be 
obtained for the new markers, defining a smaller region of interest that might be easier to 
analyse.  
 
2/ Sequencing of the whole region: if the defined region of interest is short enough to be 
sequenced as a whole, this option will be able to localize the affected gene directly. In 
addition, the whole region sequencing can be a direct proof of the number of affected genes 
in the given region.  
 
3/ Sequencing of candidate genes in the region: as the mouse genome has been deciphered 
recently, it is also possible to select few candidate genes from the region based on their 
reported functions and sequence them to check whether they are mutated in the isolated 
mutant. If candidate genes are well selected, this is the most time-efficient option.  
 
3.5.3 Phenotyping the mutation 
A significant part of the phenotyping can be done before the identity of the affected gene is 
known. However, only once the gene identity is known hypothesis can be made on its 
function and tested, resulting in more in depth phenotyping. The affected gene might be a 
novel gene or already defined gene with a new function in controlling immune responses.  
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4. This project 
The immune response of antigen-specific CD8+ T cell to viral infection is a complex, but a 
carefully regulated process controlled by a yet unknown number of genes. To understand 
this process further, we have performed an ENU mutagenesis, designed the screening 
conditions to isolate and characterize the genes required for CTL proliferation, contraction 
and memory development. By screening more than 1200 G3 mice, we have successfully 
isolated three recessive mutants, one of which, memi, also displays lymphocyte 
developmental defect. As this mutant strain has been the most extensively studied, its 
presentation constitutes the main part of this thesis. The other two mutants are currently 
under investigation and their incomplete analysis will be described in subsequent chapters. 
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Materials and Methods 
 
Mice 
C57BL/6J mice were purchased from Charles River (France). All mice for the ENU 
mutagenesis and experiments were kept and bred in Central Biomedical Services (Imperial 
College London, UK) in a pure C57BL/6J background. For the positional cloning, mutant mice 
(C57BL/6J) were bred to wild type 129Svlmj mice. For BrdU cell cycle/proliferation assay, 
mice were given freshly prepared 0.8mg/ml of BrdU (Sigma, UK) in drinking water daily for 8 
days. Mice were kept under specific pathogen free conditions in individually ventilated cages. 
All animal procedures have been authorized in the British Home Office Animals (Scientific 
Procedures) Act 1986 License Immunological memory in transgenic mice (PPL:70/6490).  
 
LCMV strains and injection  
LCMV Armstrong strain was kindly provided by Prof. Raymond M Welsh (University of 
Massachusetts Medical School, USA) at a stock concentration of 2x106 plaque forming 
units/ml in DMEM 1% FCS medium and kept at -80℃. For the screen, G3 mice were 
anaesthetized with isoflurane, injected with 2x105 pfu LCMV Armstrong diluted in sterile PBS 
intraperitoneally and kept in HEPA filter equipped isocages for the duration of the analysis. 
At days 8 and 21 after the injection, 50μl of blood was drawn from lateral vein of infected 
mice and analyzed for specific cell populations by flow cytometry. All the experiments with 
LCMV were performed in a HEPA filter equipped safety cabinet in a containment level 3 
room and apparatus used were cleaned with 1% Virkon solution. 
 
Cell preparation and counting 
The bone marrow cells were obtained from flushing femurs and tibiae with RPMI medium. 
The spleen, lymph nodes, and thymus were grinded on cell strainers and nylon mesh in RPMI 
medium to make single cell suspension. Splenocytes and blood were first subjected to a red 
blood cell (RBC) lysis step performed as follow: cells were incubated for 5 minutes at room 
temperature in RBC lysis buffer (0.85% (w/v) NH4Cl in 50mM Tris pH 7.2). Individual single 
cell preparations were then diluted in Trypan blue. The cell concentration was measured by 
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Cedex XS analyzer (Roche, UK) using Cedex XS software (Roche, UK) on individual samples. 
Cell concentration were used to calculate the absolute cell numbers of the various 
populations using percentages obtained by flow cytometry. The formula was the following: 
total cell numbers from the organ x (the percentages of particular cell polulation obtained 
from flow cytometry analysis/100). Samples from LCMV infected mice were all fixed with 1% 
paraformaldehyde (PFA) in PBS before analysis to prevent spreading of the virus. 
 
Flow cytometry 
Average of 106 cells were first incubated for 10 minutes at the room temperature with an 
anti-CD16/32 FcγR blocking antibody (eBioscience, UK) followed by 30 minutes of incubation 
with various combinations of extracellular antibodies in 1% BSA in PBS. For intracellular 
staining, cells were then fixed in 4% PFA and permeabilized in 0.01% Saponin in PBS, 
followed by 30 minutes of intracellular antibody incubation. For Annexin V, active-caspase-3, 
Yopro-1, Ki-67, anti-BrdU and 7-AAD, cells were stained according to the manufacturer's 
instruction. Samples were acquired on a DAKO Cyan 9 flow cytometer and data analyzed 
with the SummitTM software (DAKO). 
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List of antibodies for flow cytometry 
Antibody Fluorchrome Dilution Provider To mark 
CD127 (IL-7Rα) PE-Cy7 1:100 EBioscience memory precursors 
CD8 PE or Pacific Blue 1:200 BD bioscience CD8 T cells 
KLRG1/MAFA APC 1:200 EBioscience senescent CTL 
CD11c PE or eFluor450 1:200 EBioscience dendritic cells 
Ter-119 eFluor450 or PE-Cy7 1:200 EBioscience erythrocytes 
CD11b eFluor450 1:200 EBioscience macrophages 
Gr-1 APC 1:200 EBioscience granulocytes 
CD4 FITC or PE or APC or 
eFluor450 
1:200 EBioscience CD4 T cells 
CD4 Pacific Orange 1:200 Invitrogen CD4 T cells 
CD43 FITC 1:200 EBioscience B cell development 
IgM PE-Cy5.5 1:200 EBioscience B cell development 
B220 PE or APC or 
eFluor450 
1:200 EBioscience B cell development 
CD25 PE or PE-Cy7 1:200 EBioscience T cell development 
CD44 FITC or APC 1:200 EBioscience T cell development 
and proliferation 
CD62L FITC 1:200 EBioscience T cell homeostasis 
and Tcm/Tem cells 
CD122 PE 1:200 EBioscience T cell homeostatic 
proliferation 
CD69 PE-Cy7 1:200 EBioscience T cell homeostatic 
proliferation 
NK1.1 eFluor450 1:200 EBioscience NK/NKT cells 
Thy1.1 PE-Cy7 1:200 EBioscience Thy1.1+ cells 
CCR7 Pacific Blue 1:100 Invitrogen Tcm/Tem cells 
CD3 FITC or PE-Cy7 1:200 EBioscience TCR+ cells 
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FasL PE 1:200 EBioscience Fas-induced 
apoptotic cells 
gp33-iTAg MHC 
Class-I murine 
tetramer 
PE 1:40 Beckman 
Coulter 
LCMV-specific CTL 
np396-iTAg 
MHC Class-I 
murine 
tetramer 
APC 1:40 Beckman 
Coulter 
LCMV-specific CTL 
Annexin V FITC or PE 3:100 BD Bioscience apoptotic cells 
active-caspase-
3 
PE 1:5 BD Bioscience apoptotic cells 
Yopro-1  1:2500 Invitrogen apoptotic cells 
Ki-67 FITC or V450 1:5 BD Bioscience proliferating cells 
anti-BrdU 
antibody and 7-
Aminoactinomy
cin D (7-AAD) 
staining (FITC 
BrdU Flow Kit)  
FITC 1:50 for 
anti-BrdU 
antibody 
and 7-AAD 
BD Bioscience proliferating 
cells/cell cycle 
analysis 
 
Whole genomic DNA extraction and mapping 
Mouse tail tips were incubated in 0.7ml of lysis buffer (50mM Tris pH 8, 100mM EDTA, 
100mM NaCl, 1% SDS) with 1mg/ml final concentration of proteinase K (Roche, UK) at 50℃ 
for overnight. Next morning, undigested debris were removed by centrifugation (10 min, 
13000 rpm) and only the supernatant was mixed with an equal volume of isopropanol. 
Tubes were inverted several times until white stands of DNA became visible and DNA pellet 
was harvested after 5 minutes of centrifugation at 10000g. Then each pellet was washed 
with ice-cold 70% EtOH and resuspended in 0.5ml genomic DNA buffer (10mM Tris pH 8, 
0.1mM EDTA) at 37℃. DNA concentration was measured by Nanodrop machine. Genomic 
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DNA was subsequently used for sequencing (see below) orsent to KBioscience (Herts, UK) 
where a genome-wide genotyping was performed using 358 SNP markers (see annexe). The 
genetic and phenotypic linkage (LOD score) was calculated using Microsoft Excel sheet (from 
K. Hoebe, Cincinnati Hospital, USA).  
 
Sequencing of candidate genes for the mutation  
Whole genomic DNA was extracted as described above and exons were amplified by 
polymerized chain reaction (PCR) using the JumpStart REDTaq ReadyMix (Sigma, UK). The 
sets of primers which were used are listed below. PCR samples were purified by Qiagen PCR 
purification kit (Qiagen, UK) using the manufacturer’s protocol and sequenced (Genomic 
laboratory, Imperial College London, UK) by using Sequencher version 4.9 software (Gene 
Codes Corporation, USA). The setting were: initialization at 94℃ for 2 minutes, denaturation 
at 94℃ for 30 seconds, annealing at 60℃ for 30 seconds, extension at 72℃ for 90 seconds, 
final elongation at 72℃ for 5 minutes and held at 4℃.  
 
 exon primer sequence (5’ to 3’) 
dCK exon 1 Forward CGA GAT TGA CGC TGC AAC C 
Reverse AAG GGT GCA CAC TGG TCC AG 
exon 2 Forward GAT GAT GGT TGG TTA TAG TTT GC 
Reverse GCA GCT GTA GCT GGT TAG GAG 
exon 3 Forward AGC AAC GTA GTG AGA CCT TAT C 
Reverse CGC AGC CTC TAA TTT GAT TAC C 
exon 4 Forward TGT TTG AAA GGA TGT CCA TGC 
Reverse TTT CAA CAA CAC AGG CAA ATG 
exon 5 Forward ACG GCA GCA GAC ACA ACT AG 
Reverse ACA GTG AGC AGC AAC CAG C 
exon 6 Forward GCA TCA CTA CGG ATG ACG TTA G 
Reverse TGT CCT GGA CAA GAC AAG ACA C 
exon 7 Forward GGT TAT TCA ACC TAC TAC TGA AAT ACT TAG 
Reverse CCA CTC ACT GCC CTG ATG C 
Bim exon 2 Forward AGA ATC TGA GGT TGA CTC TAG 
 Reverse CTT GAC TGA TTC TAT GAG GC 
exon 3 Forward AGA AGA CCA GAG TGT GTT AG 
 Reverse TAT GTT GAG GTC TCT TGC AC 
exon 4 Forward CGG TAC ACT TGT ACT CCA TG 
 Reverse CAC ATC TCT CTG GGA TAG AAC 
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Nimblegen enrichment and sequencing  
Exonic sequences flanked by 400bp of intronic sequences on each side were obtained from 
Ensembl. The combined 1.7Mb sequence was used to generate array primers (Roche, UK). 
Whole genomic DNA was extracted as described above and subsequently hybridized on the 
array (Genome Centre, John Vane Science Centre, UK). Following elution of bound 
sequences, high throughput sequencing of the hybridized target was performed on one lane 
of an Illumina HiSeq2000 sequencer (Imperial College, UK). The data were analysed with the 
Integrated Genomic Viewer version 1.03 software (Broad Institute, USA). 
 
Cell culture 
For in vitro cell culture, splenocytes were placed at 37℃ for 1 hour and only non-adherent 
lymphocytes were harvested in RPMI medium with 10% FCS. Then they were cultured on 12-
well cell culture plates coated with 1μg/ml anti-CD3 and 2μg/ml anti-CD28 in PBS. The final 
concentration for recombinant IL-2 and IL-15 (eBioscience, UK) was 50U/ml (5ng/ml). Their 
viability was measured by Cedex XS analyzer (Roche, UK) using Cedex XS software (Roche, 
UK).  
 
CD4+ T cells purification 
Splenic CD4+ T cells were purified with a magnetic bead separation system (CD4 T cell 
isolation microbeads; Miltenyi Biotec, UK) following manufacturer’s inctructions. For the 
transfer experiments, between 3 and 5x106 of magnetically purified cells were cross-
transferred to non-irradiated congenic recipients by intravenous injection. The left over cells 
after injection were analysed by flow cytometry to check the efficiency of the purification 
system.  
 
Generation of 1:1 bone marrow chimeric mice  
Bone marrow cells were collected from femora and tibiae of Thy1.2;dCKmem/mem and 
Thy1.1;dCK+/+ donors and T cells were depleted by magnetic beads (Pan T cell isolation kit; 
Miltenyi Biotec, UK). The purified cells from each genotype were mixed 1:1 and total of 106 
cells were intravenously injected per recipient which were treated with Baytril for the 
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duration of the experiment. Recipients were analyzed 5 weeks after injection.  
 
DCK kinase activity assay  
Protein (1μg/μl concentration) was extracted by M-PER Mammalian Protein Extraction 
Reagent (Pierce, UK). DCK activity was measured using 3H-labelled-2-CdA as a substrate. 
DCK activity was initiated by incubation of protein lysate (5ug) in DCK buffer (50mM Tris-HCL 
(pH 7.6); 5mM UTP; 5mM MgCl2; 2mM DTT; 10mM NaF; 1mM Thymidine), and the addition 
of 1uCi 3H-CdA in final volume of 10μl. Reactions were carried out in 96 well plates at 37℃ 
for 20 minutes, quenched with 40μl ice-cold water and heated at 90℃ for two minutes. The 
96 well-plate was then transferred to a harvesting machine (Tomtec harvester 9600; Tomtec, 
USA) and the reaction mixture was aspirated onto a wallac filter mat (Wallac 1450-421; 
PerkinElmer, UK) and washed three times in PBS. The filter mat was washed three times for 
5 minutes in 200 ml of 4mM ammonium formate. Further washing was performed for 2 
minutes in 95% ethanol twice. Following washes, the filter mat was placed in 60℃ oven for 
10 minutes prior to addition of scintillation fluid. Enzyme kinetic properties were calculated 
by linear regression analysis using Michaelis–Menten plots. Values where determined from 
the graph and calculated as nM per minute per μg DCK protein. 
 
Real Time Reverse Transcription PCR 
To obtain total mRNA, a half of whole spleen was homogenised in 1ml of TRIzol (Invitrogen, 
UK) and 0.2ml of chloroform was added for the phase separation by centrifugation. The 
upper clear phase where mRNA remained was carefully taken and 0.5ml of isopropanol was 
added to precipitate mRNA. The mRNA pellet was washed with 75% ethanol and the dried 
pellet was dissolved in DEPC-treated water to measure its concentration using Nanodrop 
machine. cDNA was synthesized using oligo(DT)20 with the SuperScript III Reverse 
Transcriptase Kit (Invitrogen, UK) according to the manufacturer’s instructions. 
10~100ng/well of cDNA with specific primers (Jordheim et al., 2004a) was mixed with SYBR 
green (Applied Biosystems, UK) following the manufacturer's instructions and loaded into 
the 7900HT Fast Real-Time PCR System (Applied Biosystems). The setting was: initialization 
at 95℃ for 10 minutes, denaturation at 95℃ for 15 seconds, annealing and extension at 55℃ 
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for 1 minute, dissociation stage, and held at 4℃. The data was analysed by Microsoft Excel 
sheets.  
 
SDS PAGE and Western blot 
Cells were lysed in NETN buffer (0.5% NP40, 20mM Tris-HCl pH 8, 0.1M NaCl, 1mM EDTA) at 
-20℃ for 30 minutes and supernatant was harvested for protein assay to measure the 
concentration (Pierce 660nm protein assay reagent; Thermo Sceintific, UK). Fifteen to 
twenty μg of proteins were mixed with an equal volume of 2X SDS PAGE lysis buffer (64mM 
Tris-HCl pH 6.8, 10% (v/v) glycerol, 2% SDS, 0.05% (v/v) β-mercaptoethanol, and 
bromophenol blue trace in distilled water) and boiled at 100℃ for 10 minutes. Samples 
were size fractionized by SDS-PAGE and electrophoretically transferred onto nitrocellulose 
membrane (GE Healthcare, UK) by applying 100V for 1 hour in cold transfer buffer (25mM 
Tris, 250mM glycine, 0.1% SDS and methanol). Then the membrane was kept in 5% (w/v) 
dried skim milk powder in PBST (0.1% (v/v) Tween in PBS) for 1 hour before incubation with 
primary antibody in BSA solution (5% (w/v)BSA, 0.05% (v/v) aside in PBST) at 4℃ overnight 
with gentle agitation. The next day, the membrane was washed 3 times 10 minutes with 
PBST, incubated with the appropriate horse raddish peroxidise (HRP)-conjugated secondary 
antibody in 5% (W/V) dried skim milk powder in PBST for 1 hour atroom temperature with 
gentle agitation. Any residual antibody was removed by 3 times 10 minutes washes in PBST, 
followed by a final wash with PBS prior to visualisation using the ECL detection system (GE 
Healthcare, UK). Primary antibodies used are all from Santa Cruz, USA, unless otherwise 
stated: dCK(ABcam, UK), cyclin A (C-19), cyclin D3 (18B6-10), p27Kip1 (C-19), actin (ABcam, 
UK), pRB (C-15), Foxo3a (Millipore), MAPK family antibody sampler kit (Cell Signalling, UK), 
phospho-MAPK family antibody sampler kit (Cell Signalling, UK) and phospho-Akt pathway 
antibody sampler kit (Cell Signalling, UK). Secondary antibodies used are: rabbit anti-goat 
IgG (SouthernBiotech, USA), goat anti-rabbit immunoglobulin (Dako, UK), goat anti-mouse 
immunoglobulin (Dako, UK). dCK (ABcam) 
 
Statistical analysis 
All results are given as mean values with standard deviation (SD), unless otherwise stated. 
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Nonparametric unpaired t-test (two-tailed) was used to perform group comparison, and p 
values indicated: *p<0.05, **p<0.01, ***p<0.001 significance. All statistic calculations were 
performed with the Prism5 software (Graphpad, USA). 
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Results 
 
PART 1: ENU mutagenesis and screening  
 
To discover new regulators of CD8+ T cell immune response and memory formation upon 
acute viral infection, we performed an ENU germline mutagenesis on C57BL/6J mouse. We 
screened G3 mice produced by our 3 generation breeding scheme for recessive mutations 
and successfully isolated 3 mutants with altered immune response to LCMV Armstrong 
infection. In this section, we will present how the ENU mutagenesis was performed and how 
screening parameters were defined and adjusted to optimise efficiency. 
 
1. ENU mutagenesis and breeding 
To create mutant mice, three weekly dose of ENU were injected to an overall total of 154 
C57BL/6J wild type male mice (generation G0). Between 10 and 15 G0 males were injected 
every week over a period of 3 weeks. As described in the introduction, ENU is highly toxic, 
the mice survival rate and time it takes them to recover fertility were directly proportional 
to the ENU dose injected. Initially, mice received 3 times 100mg ENU/kg body weight (as 
described in Justice et al, 2000 (Justice et al., 2000b)). Their lethality rate was very high since 
only a few males survived more than 17 weeks after injection (Fig. 8a). In addition, only 48% 
(12 out of 25 mice) of them ever recovered fertility (Fig. 8b), therefore preventing us from 
obtaining enough G1 males for further breeding. We consequently lowered the ENU dose to 
3 injections of 90mg ENU/kg each, considerably improving survival and fertility (Fig. 8). This 
dose was enough to induce mutations since phenodeviants were isolated in the progeny of 
these males.  
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Figure 8: Effect of ENU doses on the survival and the fertility of G0 males 
(a) Each column represents the percentage of mice from each group found dead on the 
indicated week following the last ENU injection. All mice found dead after week 17 are 
represented in the last column. (b) Each column represents the percentage of mice from each 
group and the week they recovered their fertility following the last ENU injection. The mice 
that have not recovered fertility by week 16 after the last ENU injection are represented in the 
last column. For both graphs, n=25 for 100mg ENU/kg body weight and n=55 for 90mg 
ENU/kg body weight. 
 
Once ENU injected males recovered their fertility, they were bred to wild type C57BL/6J 
females to obtain G1 males. These males were mated with wild type females to produce G2 
daughters of which two were backcrossed to their fathers. At 6 weeks of age, G3 females 
were screened with LCMV Armstrong to isolate phenodeviants which had a distinctive 
immune response to LCMV.  
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Figure 9: Backcross breeding scheme used during our mutagenesis  
The red arrow indicates ENU injection. A G0 C57BL/6J male is injected with 3 weekly dose 
of ENU and bred to wild type females to obtain G1 males. Then they are mated with wild 
type females to produce G2 daughters which are backcrossed to their fathers. G3 females are 
screened for isolating phenodeviants.  
 
The summary of the overall ENU mutagenesis is represented in Table 4. 
 
#Males injected with ENU (G0) 154 
#G1 males bred to wt females 720 
#G2 females bred to G1 father 1019 
#G3 females screened 1263  
Table 4: Summary of the mutagenesis results 
G3 females were screened for their immune response to LCMV Armstrong infections and G3 
males were kept for another project.  
 
2. Setting of the screening parameters  
To maximize the efficiency of our screen and allow us to isolate rare individual 
phenodeviants, we had to determine the best screening conditions. First, the screening 
process had to be simple and rapid because it had to be performed on a large number of 
mice every week. We indeed planned to screen a minimum of 50 mice a week, every week. 
Second, the Standard Deviation (SD) for each parameter had to be as small as possible in 
WT
WT
Females for 
screening 
phenodeviants
C57BL/6J
ENU
G0
G1
G2
G3
males
females
heterozygous
homozygous
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order to define cut off values that would prevent us from isolating too many false positive 
individuals. 
 
2.1 Ag-specific cells and apoptosis 
In order to isolate individual G3 phenodeviants, it is crucial to measure parameters that are 
as reproducible as possible in wild type mice. To do so, we first established the mean and SD 
values for our different parameters in pure C57BL/6J wild type mice (directly obtained from 
Charles River). Six weeks old females were infected with 2x105 plaque forming units (pfu) of 
LCMV Armstrong intraperitoneally and bled at day 8 and day 21. To assess the expansion 
and proliferation of Ag-CTL, blood samples were incubated with an anti-CD8 antibody and a 
PE-conjugated H-2Db MHC class I tetramer which specifically recognize LCMV glycoprotein 
gp33-41 antigen peptide (gp33) bound to the MHC. As a direct measurement of apoptosis, 
samples were incubated with Yopro-1, a DNA intercalant dye which is specific for early 
apoptotic cells (Baudouin et al., 2007; Idziorek et al., 1995; Plantin-Carrenard et al., 2003). 
The data were analysed as represented in figure 10 and the values obtained are shown in 
figure 11. Although Yopro-1 staining gave a slightly high SD, it was not excluded from our 
screening parameters as it could be an indicator to isolate genes which control CTL 
contraction. Other apoptotic indicators could have been used such as Annexin V or active-
caspase 3 antibodies, but they were not ideal for a large-scale screening as the stainings are 
very time and money consuming as compared to Yopro-1.  
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Figure 10: Defining the percentages of gp33-specific CD8+ cells and Yopro-1+ Ag-CD8 
cells in lymphocytes  
A pulse width-forward scatter (FS) plot allowed us to exclude non-singlet cells. A gate was 
then applied on the lymphocytic population to define the population of CD8+ cells. A further 
step allowed us to define the percentage of Ag-CTL (as defined as gp33+ cells in the 
population of CD8+ lymphocytes). In this example, 8.5% of CD8+ cells are gp33-specific. 
Finally, the percentage of gp33+-CTL apoptotic cells was defined by gating on the double 
positive gp33+CD8+ population. In this example, 4.4% of gp33+CD8+ cells are Yopro-1+.  
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Figure 11: Average percentage of cells in LCMV-infected wild type C57BL/6J female 
mice 
LCMV-specific cells were detected by a gp33-specific tetramer and an antibody against 
CD8+ cells. Apoptotic cells by staining with Yopro-1. The percentage of gp33+ cells in the 
CD8+ population is 8.9% ± 1.2% at day 8, and 5.9% ± 1.2% at day 21. The percentage of 
apoptotic cells is 4.8% ± 3.1% at day 8 and 5.0% ± 4.6% at day 21. A total of 31 wild type 
mice were tested in 3 independent experiments. The bars represent the mean value ± 1 SD. 
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53 
 
2.2. Proliferation 
To isolate mutations in regulators of quiescence, we originally intended to assess the 
proliferation status of the Ag-CTL at the peak of expansion and end of contraction by 
performing a bromodeoxyuridine (BrdU) pulse-chase experiment. In theory, if mice are 
given BrdU for the first 8 days after LCMV infection, Ag-specific CD8 effector cells which are 
rapidly proliferating will incorporate BrdU into their DNA. When the same animals are then 
given normal water, the BrdU signal in actively dividing effector cells will be diluted into the 
daughter cells and only slowly dividing memory precursor CD8+ T cells will retain a high BrdU 
level by day 21 (fig. 12).  
 
 
Figure 12: BrdU pulse-chase experimental plan to measure proliferation and entry into 
quiescence of Ag-CTL 
After infection with LCMV, mice are given BrdU water for 8 days and normal water until 
day 21 bleeding. All proliferating cells will incorporate BrdU during DNA synthesis and will 
therefore be BrdU+. After 2 weeks without BrdU (normal water), slowly dividing/quiescent 
cells will still be BrdU+, whereas cells that are actively proliferating will have diluted their 
BrdU content and will appear to be BrdUlow. 
 
However, this BrdU pulse-chase protocol had several disadvantages. The requirement for 
cell permeabilisation is incompatible with the Yopro-1 staining and it requires 1 to 2 hours 
of DNAse treatment which considerably impairs high throughput efficiency. Because of 
these reasons, we had to find alternatives to the BrdU pulse chase method. 
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To assess the level of proliferation, two markers were investigated: Ki-67 because it is only 
expressed on actively dividing cells (non-G0 cells) (Gerdes et al., 1984a) and killer cell lectin-
like receptors member G1 (KLRG-1) because it is expressed on senescent cells which have 
divided for more than 10 times (Voehringer et al., 2001). In combination with IL-7Rα 
(CD127), a marker known to be expressed on memory precursor, KLRG-1 can be used to 
define the population of proliferating effector cells (KLRG-1+IL-7Rα-) and the population of 
memory precursors (KLRG-1-IL-7Rα+)(Joshi et al., 2007). To assess whether there is a 
potential correlation between BrdU’s incorporation and the expression of these markers, 
wild type mice were infected with LCMV, given BrdU for 8 days, bled, given normal water 
and bled at day21 post-infection.  
We first compared KLRG-1 expression and BrdU incorporation on Ag-CTL at both day 8 and 
21. Samples were stained for gp33, CD8, BrdU, KLRG-1 and IL-7Rα and analysed as 
represented in figure 13. The results are represented in figure 14. 
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Figure 13: Defining the percentage of BrdU+KLRG1+gp33+CD8+ lymphocytes 
Acquired data are gated on singlets and the lymphocyte population is defined. This gate is 
directly applied to define the gp33+CD8+ population. To determine the correlation between 
KLRG-1 expression and BrdU incorporation, the population of KLRg-1+IL-7Rα- effector 
gp33-specific CD8+ T cells is defined and analysed for simultaneous expression of KLRG-1 
and BrdU. 
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Figure 14: KLRG-1 expression and BrdU incorporation in the population of gp33+CD8+ 
cells at day 8 and day 21 post LCMV infection 
The percentage of BrdU+ cells in the population of gp33-specific CD8+ cells is represented by 
the white column at both days. The values are 87.5% ± 1.7% at day 8 and 55.2% ± 9.8% at 
day 21. The grey columns (KLRG1+/BrdU+) represent the percentage of KLRG-1+iIL-7Rα- 
cells which also are BrdU+ at both days (94.6% ± 2.3% at day 8 and 51% ± 9.8% at day 21). 
The percentage of KLRG-1+IL-7Rα- cells in gp33+CD8+ T cells at both days are indicated as 
the black columns (83.6% ± 3.5% at day 8 and 39.8% ± 9.5% at day 21). A total of 31 wild 
type mice were tested over 3 experiments, but only 1 representative experiment is shown 
(n=5). The error bars represent SD. 
 
At day 8 post-infection, 88% of gp33-specific CD8+ T cells are BrdU+, indicating that they 
have synthesised DNA during this period while 80% of the Ag-CTL are KLRG-1+. The 
percentage of KLRG-1+ cells that are also BrdU+ is 94.8%. There is therefore a very high 
correlation between BrdU incorporation and KLRG-1 expression in Ag-CTL at day 8 post 
LCMV infection.  
On the contrary, at day 21, the percentage of gp33+CD8+ cells expressing KLRG-1 and BrdU is 
only 50%, indicating a loss of correlation between KLRG-1 expression and BrdU 
incorporation at this time point. 
 
We also investigated the correlation between Ki-67 expression and BrdU incorporation. 
Staining cells with both BrdU and Ki-67 antibodies was impossible as those markers require 
different treatment procedures. Mice were therefore challenged as described above but 
samples were stained with anti-human Ki-67 antibody in combination with gp33, CD8, KLRG-
1 and IL-7Rα. This allowed us to compare Ki-67 expression to KLRG-1 expression as we have 
found a good correlation between BrdU and KLRG-1 expressing cells at day8 (fig. 14). The 
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data were analysed for lymphocytes, gated on the population of gp33 specific CD8+ cells and 
the percentages of Ki-67+, KLRG-1+ and IL-7Rα+ cells were measured (fig. 15).   
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Figure 15: Ki-67 expression in gp33+ CD8 cells at day 8 and day 21 
The values of BrdU+ lymphocytes obtained in the previous experiment (fig. 14) are 
represented by the white column as a reference (87.5% ± 1.7% at day 8 and 55.2% ± 9.8% at 
day 21). The percentages of Ki-67+ cells are in light grey (25.5% ± 3.0% at day 8 and 5.6% ± 
1.3% at day 21). The percentages of KLRG-1+Ki-67+ cells are in dark grey (KLRG-1+/Ki-
67+)(12.8% ± 3.7% at day 8 and 4.3% ± 2.6% at day 21), and the percentages of IL-7Rα+Ki-
67+ cells are in black (IL-7Rα+/Ki-67+) (19.1% ± 7.5% at day 8 and 3.2% ± 1.7% at day 21). 
The bars represent the SD, n=5. 
 
The percentages of Ki-67 expressing cells for both days is very low compared to the 
percentage of BrdU incorporating cells, indicating an absence of correlation between Ki-67 
expression and BrdU incorporation at both days of analysis. 
 
As an alternative to the measurement of the population of quiescent cells at day 21 (BrdU+ 
cells), we assessed the expression of IL-7Rα in gp33+CD8+ cells. IL-7Rα has been described as 
a marker for memory precursors (Joshi et al., 2007). Mice were challenged as above and day 
21 samples stained for gp33, CD8, KLRG-1, IL-7Rα and BrdU (KLRG-1 was used here to define 
the population of KLRG-1-IL-7Rα+ memory precursors). The analysis was performed as 
described in figure 13 except that the population of IL-7Rα+KLRG-1- was now considered. 
The results are represented in figure 16. 
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Figure 16: IL-7Rα and BrdU expression in the population of gp33+CD8+ cells at day 21 
post LCMV infection 
The percentage of BrdU+ cells in the population of gp33-specific CD8+ cells is represented by 
the white column (55.2% ± 9.8% at day 21). The grey column represents the percentage of 
KLRG-1-IL-7Rα+ cells that are BrdU+ (IL7R+/BrdU+) (63.2% ± 8.8% at day 21). The 
percentage of KLRG-1-IL-7Rα+ cells in the gp33+ CD8+ T cell population is indicated as the 
black column (18.0% ± 5.2% at day 21). A total of 31 wild type mice were tested over 3 
experiments, but only 1 representative experiment is shown (n=5). The bars represent the SD.  
 
These results indicate that, in the population of gp33+CD8+ cells, 65% of IL-7Rα expressing 
cells are also BrdU+ (quiescent cells). This indicates a positive correlation between the two 
markers at day 21 post infection.  
 
From the results obtained with these 3 alternative markers, we decided to change our 
original BrdU proliferation screening protocol for a measurement of the 2 extracellular 
markers KLRG-1 at day 8 and IL-7Rα at day 21. As a result, the new screening protocol (fig. 
17) consisted in infecting the mice with LCMV, bleeding them at day 8 and day 21, staining 1 
sample only per mouse for the extracellular markers gp33, CD8, KLRG-1 and IL-7Rα and for 
Yopro-1, and analysing them as represented in figure 18. This protocol had been used to 
screen all the G3 mice presented in the rest of this project. 
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Figure 17: Schematic diagram of LCMV Armstrong screening  
G3 mice were injected with LCMV Armstrong at their age of 6 weeks old and bled at day 8 
and day 21 post infection to analyse their immune responses by gp33, CD8, IL-7Rα, KLRG-1 
and Yopro-1. 
 
 
Figure 18: Sample analysis protocol used for the screen 
Only singlets are considered. The population of CD8+ cells is defined and this gate is used to 
determine the percentages of gp33+ cells in the CD8+ population. By gating on the 
gp33+CD8+ population, the percentage of apoptotic cells (Yopro-1+), of effector KLRG-1+IL-
7Rα- and of memory precursor/quiescent IL-7Rα+KLRG-1- cells is determined. A minimum 
of 10,000 gp33+CD8+ cells are acquired at day 8 and a minimum of 5,000 at day 21. 
 
2.3 Screening controls 
In order to identify rare phenodeviants without isolating too many false positives, mean 
values and SD had to be defined as precisely as possible for all the parameters we were 
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analysing. During the first 6 weeks of the screen, 31 C57BL/6J wild type female mice were 
purchased and tested together with the G3 female mice from our mutagenesis. As shown in 
table 2, the average percentage of gp33-specific CD8+ cells is 8.8% and 8.9% at day 8 for G3 
and wild type, respectively but the percentages changed to 6.7% and 5.9% at day 21, 
respectively. There is approximately a 2% difference between G3 and wild type values in the 
percentage of KLRG-1+ gp33-specific CD8+ cells at day 8 and day 21. In addition, the 
percentage of IL-7Rα+ expressing gp33+CD8+ cells also shows a slight difference between G3 
and wild type mice at both days. We therefore observed a slight difference in all screening 
parameters between the mean and the SD of wild type and G3 animals at day 8 and at day 
21. What we originally planned was to use pure wild type controls’ (that is purchased 
C57BL/6J mice) mean and SD to identify G3 phenodevients of interest. However, because 
the average values for G3 and wild type mice were quite different (table 5), we decided to 
use the G3 values themselves as an internal control for each week’s screening. 
 
 d8 d21 
G3 wt G3 wt 
Number of animals 170 31 170 31 
%gp33+ in CD8+  8.8±1.5 8.9±1.2 6.7±1.2 5.9±1.2 
%KLRG-1+ in gp33+CD8+ 78.8±4.7 76.9±5.2 47.8±11.4 50.8±7.1 
%IL7Rα+ in gp33+CD8+ 4.3±1.4 5.1±1.9 11.4±4.1 10.9±3.5 
Table 5: Differences between G3 and wild type mice in response to LCMV Armstrong 
infection 
This table represents the mean values ± SD (%) obtained from the first 6 weeks of screening. 
 
To determine the cut off values for our screen, the mean ± 2SD of G3 animals that were 
screened each week were used. Based on the hypothesis that our mice are following a 
Gaussian distribution, 95% of them should be in the range of mean ± 2SD. Any individual 
outside of this range was therefore considered to be a phenodeviant and its parents and 
additional offspring were isolated from the cohort for further analysis.  
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3. Screen results and isolation of mutants 
 
Between September 2008 and August 2009, we screened total of 1263 G3 mice for their 
immune response to LCMV Armstrong infection (Fig. 19). 
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Figure 19: Screening results for all weeks at both day 8 and 21 from September 2008 to 
August 2009 
Each dot represents a single G3 mouse (n=1263). Error bars indicate 2SD. (a) %gp33+ in 
CD8+ cells, (b) %Yopro-1+ in gp33+CD8+ cells, (c) %KLRG-1+IL-7Rα- in gp33+CD8+ cells 
and (d) % KLRG-1-IL-7Rα+ in gp33+CD8+ cells.  
 
All phenodeviants which had been found are summarized in table 6. Once a phenodeviant 
mouse was identified in the screen, we had to check that the mutation was transmissible in 
the germline and was not a somatic mutation or a false positive. To do so, new G3 offsprings 
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from the same parents were screened and the ratio of mutant mice recorded. In theory and 
according to the Mendelian model of inheritance (see introduction) when both parents are 
heterozygous for a mutation and the penetrance of the mutation is 100%, the probability of 
having 1 homozygous G3 animal is 1/4. If the mutation is recessive, this will translate as 25% 
mutant in the G3 progeny. If the results obtained with the new G3 offspring failed to satisfy 
this ratio, we considered the initial phenodeviant mouse to be a false positive. For example, 
phenodeviant #1 was initially found to have 24% of IL-7Rα+ gp33+CD8+ cells at day 21 while 
the internal controls had an average of 12.5% (SD=4.3%). However, from the result obtained 
with 13 of its siblings, it appeared that this mutation was far from being present in 25% of 
the G3 animals. Therefore, we classified it as a false positive hit. Of course, we could not 
exclude that this mutation was a germline mutation with a lower penetrance rate. However, 
we decided not to work on mutations with low or incomplete penetrance as it would have 
been much more complicated to genotype, map and establish homozygous breeding pairs.  
 
Except for these false positive hits, we have successfully isolated 3 mutants called memi, 
binu and alois, of which phenotypes will be discussed further in this thesis. 
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# phenodeviant/ 
initial G3 mice 
tested 
Phenotype phenodeviant/ 
retested G3 mice 
Mutant? 
1 1/2 Increased %IL-7Rα+ in Ag-CTL 
at day 21 
0/13 No 
2 1/2 Increased %IL-7Rα+ in Ag-CTL 
at both days 
0/10 No 
3 1/3 Continuous increase in %Ag-
CTL 
0/8 No 
4 1/5 Increased %Ag-CTL at both 
days 
0/10 No 
5 1/3 Decreased %KLRG-1+ in Ag-
CTL at day 8 
0/12 No 
6 1/3 Increased %KLRG-1+ in Ag-
CTL at day 21 
1/12 No 
7 1/4 Increased %Ag-CTL at day 8 0/7 No 
8 1/3 Increased %KLRG1+ and 
decreased %IL7R+ at day 8 
5/12 memi 
9 1/3 Decreased %KLRG1+ and 
Increased %IL7R+ at both 
days 
2/6 binu 
10 1/3 Increased %Ag-CTL at both 
days 
0/7 No 
11 2/3 Increased %Ag-CTL at day 21 0/7 No 
12 1/3 Increased %Ag-CTL at both 
days 
0/9 No 
13 1/3 Decreased %Ag-CTL at both 
days 
0/9 No 
14 1/3 Increased %IL7R+ at day 21 0/9 No 
15 2/3 Increased %KLRG1+ at both 
days 
4/7 alois 
16 2/2 Decreased %KLRG1+ and 
increased %IL7R+ at day 21 
0/10 No 
Table 6: Phenodeviants isolated from the LCMV screens 
The first column represents the phenodeviant number (#), the number of phenodeviants/total 
number of initial G3 mice tested is shown in the second column, followed by the phenotypes 
of isolated phenodeviants and the number of phenodeviants/total number of G3 mice in the 
retest. Among these phenodeviants, only phenodeviants #8, 9 and 15 are proven to be 
transmissible germline mutations.  
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PART 2: memi 
 
Background 
 
1. Homeostatic proliferation  
In early life, the single positive (CD4+CD8- and CD4-CD8+) T cells migrate from the thymus to 
the peripheral organs to provide cellular immune responses to infections throughout life. 
For their long-term survival, these peripheral T cells require continuous low-affinity contact 
with self peptide-MHC complex via the T cell receptor (TCR) and a sufficient supply of IL-7 
(Surh and Sprent, 2008). Typically, mature resting T cells which have just migrated from the 
thymus are naive (CD44lo) and express high levels of lymph node homing receptors, mainly 
CD62L (Walker et al., 1995). In the secondary lymphoid organs, naïve CD8+ T cells receive 
signals from self peptide-MHC complex and survival cytokines (IL-7 and/or IL-15) from 
dendritic cells and fibroblastic reticular cells. These combined external signals induce the 
activation of the JAK-STAT pathway which initiates the production of Bcl-2 and Mcl-1 to 
prevent mitochondria-induced apoptosis by inhibiting pro-apoptotic Bim and Bax. This 
homeostatic mechanism controls the proliferation of naive T cells to maintain the overall T 
cell pool size at an adequate level.  
This balance between slow homeostatic turn-over of peripheral T cells and intense 
proliferation can be easily disturbed. For example, in a lymphopenic environment, the 
availability of peptide-MHC complexes and the relative concentration of IL-7 will increase, 
leading to an extensive proliferation called homeostatic proliferation. This is for example the 
case when naïve T cells are adoptively transferred to acute lymphopenic recipients (e.g 
irradiated hosts) (Goldrath and Bevan, 1999). This type of homeostatic proliferation is also 
called lymphopenia-induced proliferation (LIP). The donor cells which undergo LIP in a 
lymphopenic environment upregulate the expression of CD44 and downregulate the 
expression of CD62L in a manner characteristic of fully activated effector cells (Goldrath and 
Bevan, 1999). 
Another type of homeostatic proliferation is driven by the relative higher abundance of γ-
cytokines other than IL-7, as IL-2 or IL-15. For example, in CD132 (common γ-chain)-deficient 
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mice, adoptively transferred wild type donor cells rapidly proliferated while retaining high 
expression of CD62L (Cho et al., 2007). The relative abundance of γ-cytokines drives 
proliferation of CD8+ T cells preferably than CD4+ T cells. 
Finally, in chronic lymphopenic environment, like SCID and RAG-deficient mice, homeostatic 
proliferation is also driven by antigens from the gut (commensal microorganisms). While 
most of naive T cells transferred to chronic lymphopenic hosts undergo relatively slow 
proliferation driven by low-affinity peptide-MHC molecules and IL-7, a subset of naive T cells 
proliferate rapidly in response to the commensal microflora (Kieper et al., 2005). These T 
cells also upregulate CD44 and downregulate CD62L expression (Min et al., 2005). This form 
of proliferation is referred as chronic lymphopenia-induced proliferation (cLIP).  
 
2. Deoxycytidine kinase (dCK) 
2.1 The deoxyribonucleoside de novo and salvage pathways   
There are two major pathways which provide purine and pyrimidine nucleotides to the 
dNTP pool: the de novo and the salvage pathways. In the de novo pathway, ribonucleotide 
reductase (RNR) is a key enzyme which reduces the 2'-hydroxyl group of ribonucleoside 5'-
diphosphates to the corresponding ribonucleotides, using ATP for its activation (Brown and 
Reichard, 1969). Cells in the S-phase of the cycle have the most pronounced RNR activity 
while RNR activity in resting cells is much lower (Bianchi et al., 1997).  
 
The deoxyribonucleoside salvage pathway is an alternative route which provides nucleotides 
for DNA synthesis (fig. 20). It recycles free deoxyribonucleosides from the extracellular 
space. These free deoxyribonucleosides derive from nutrients or degraded DNA from nearby 
apoptotic cells. They are transported into the cytosol by low affinity facilitated two-way 
diffusion which takes place in almost all cell types, or by sodium dependent active transport 
by carrier proteins with high substrate affinity and specificity (Kraupp and Marz, 1995). Once 
in the cytoplasm, nucleosides are phosphorylated into their NMP form by either 
deoxyxytidine kinase (dCK) or thymidine kinase 1 (TK1). This process is the rate limiting step 
of the salvage pathway. Nucleosides which are used for mitochondrial DNA synthesis are 
phosphorylated by thymidine kinase 2 (TK2) and deoxyguanosine kinase (dGK) in the 
mitochondria (Eriksson et al., 2002). Subsequently, those phosphorylated NMP are further 
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phosphorylated by different enzymes to become triphosphate forms which migrate into the 
nucleus and are used as DNA building blocks. While the de novo pathway provides dNTP for 
DNA replication and cell proliferation during the S-phase, the salvage pathway is essential 
for (summarized in Arner and Eriksson, 1995): 
 
1/ In Sphase thymocytes, pyrimidines are provided by the salvage pathway while purines are 
produced through the de novo pathway, 
2/ In cells which are not in S-phase, deoxyribonucleotides are supplied by the salvage 
pathway for DNA repair and mitochondrial DNA replication,  
3/ The salvage pathway contributes to the maintenance of the dNTP pool balance to 
prevent DNA mutation, 
4/ Enzymes involved in the salvage pathway have critical roles in effective anticancer 
chemotherapeutic treatment.  
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Figure 20: The nucleoside salvage pathway 
Once free nucleosides enter into the cytosol, they are phosphorylated by dCK and TK1 (for 
mitochondria, by TK2 and dGK), and further phosphorylated to their triphosphate forms. 
ECM, extracellular matrix; CDA, cytidine deaminase; DA, dCMP deaminase; TS, 
thymidylate synthase; AK, adenylate kinase; GMPK, guanylate kinase; CMPK, cytidylate 
kinase; TMPK, tymidylate kinase; NDPK, nucleotide diphosphate kinase (adopted from Toy 
et al. 2010) 
 
Besides dCK and TK1, there are other enzymes involved in purine nucleoside metabolism, 
such as adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) which 
converts adenosine into inosine and inosine into hypoxanthine respectively.  
 
2.2 dCK 
The murine dCK gene is found on chromosome 5 and spreads over 18.29kb (Ensembl 
assembly 37). DCK is detectable in the bladder and the gastrointestinal tract, but the highest 
enzymatic activity is found in lymphocytic organs such as bone marrow, thymus and spleen 
(Toy et al., 2010). It has been reported that a complete knock-out of dCK in the mouse 
causes defects in lymphocyte development and splenomegaly (Toy et al., 2010).  
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The amount of mRNA does not seem to reflect DCK activity, which implies that there might 
be post-translational regulation of the gene products (Hengstschlager et al., 1993). DCK is 
composed of 2 homodimers and each subunit is composed of 260 amino acids weighing 
30kDa (Arner and Eriksson, 1995). As a key enzyme of the nucleoside salvage pathway, DCK 
converts deoxyadenosine, deoxycytidine and deoxyguanosine to dAMP, dCMP and dGMP, 
respectively, by using UTP, ATP or other phosphate donors (Hughes et al., 1997). In addition 
to nucleosides, DCK also phosphorylates anticancer or antiviral deoxyribonucleosides such 
as lamivudine, cytosine arabinoside and gemcitabine (Eriksson et al., 2002). Therefore, a 
mutation in dCK causing reduction in DCK phosphorylation activity can induce gemcitabine 
resistance in cancerous cells (Galmarini et al., 2004).  
 
Our memi mutant is a complete loss-of-function allele of dCK. In addition to its abnormal 
expansion of short-lived effector cells and reduction in memory precursor cells upon LCMV 
infection, this mutant also presents several lymphocyte developmental defects. Moreover, 
our data on memi show for the first time the relationship between DCK and lymphocytes 
homeostasis in both a cell-intrinsic and a cell-extrinsic manner.  
 
Results 
 
1. Isolation of the memi mutation 
As described above, our mutagenesis and screening strategy allowed us to isolate 
phenodeviants with altered immune response to LCMV Armstrong infection. After screening 
727 G3 mice, we isolated our first germline transmissible mutation that we called memi. 
Memi stands for memory IL-7Rα phenotype. Uninfected (naive) memi mutants breed 
normally and are healthy up to at least 13 months of age. In response to LCMV infections, 
homozygous memi mutants present a significant increase in antigen-specific effector cells 
(gp33+CD8+KLRG-1+IL-7Rα-) and a decrease in memory precursors (gp33+CD8+KLRG-1-IL-7Rα+) 
(fig. 21).  
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Figure 21: memi mice were isolated by their distinctive immune response upon LCMV 
infection 
6-weeks old G3 mice were injected with LCMV and their antigen (gp33) -specific CD8+ T 
cell immune response in the blood was analysed for the expression of KLRG-1 (left) and IL-
7Rα (right). These graphs represent a part of the LCMV screening results including 6 memi 
and 9 G3 mice. In all experiments, statistical analysis was performed as described in the 
material and methods. Wild type littermates are represented as closed circles (●), and memi 
mice are represented as open circles (o). Error bars represent standard deviation unless 
otherwise stated and *p<0.05, **p<0.01, ***p<0.001. 
 
The memi mutation behaved in a recessive manner as the ratio of homozygous offspring 
obtained from breeding different combinations of parents follows the Mendelian laws of 
inheritance for recessive mutations (table 7).  
 
 # memi 
mutants 
# total offspring 
tested 
Mutant 
ratio 
Expected Mendelian ratio 
for a recessive mutation 
Het x WT 0 10 0 0 
Het x Het 11 36 30% 25% 
Hom x Het 24 52 46% 50% 
Table 7: memi behaves as a recessive mutation 
Mutant ratios obtained by testing offspring from parents of different combinations of 
genotypes are comparable to expected Mendelian ratios for a recessive mutation.  
 
For all the phenotypes observed and described here, heterozygous memi mice (memi-/+) 
were indistinguishable from wild type mice in their phenotypes (fig. 22). We therefore used 
heterozygote littermates as wild type controls for most experiments and they are indicated 
as “wt” in the figures from now on unless otherwise stated. 
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Figure 22: memi heterozygous littermates are indistinguishable from wild types in their 
immune responses to LCMV infection 
6-weeks old wild type, memi heterozygous and homozygous mice were injected with LCMV 
and their antigen (gp33) -specific CD8+ T cell immune response in the blood (a) was 
analysed for the expression of Yopro-1 (b), KLRG-1 (c) and IL-7Rα (d). memi heterozygous 
mice are represented as half open circles (◐). Here, n=28 for wild type mice, n=5 for memi 
heterozygous and n=5 for homozygous mice.  
 
Interestingly, the percentages of Ag-CTL at day 8 and day 21 post-infection were variable 
among memi individuals (fig. 23). Some mutant mice presented more than 20% of Ag-CTL at 
day 8 post-infection (average 8% of Ag-CTL in wild type controls) while some mice showed 
undetectable levels of Ag-CTL at the same time point. In addition, some mice did not seem 
to follow the conventional expansion-contraction model of CD8 immune response. For 
example, memi mice indicated with red and circles did not show any decrease in the 
percentages of Ag-CTL at the end of the contraction phase.  
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Figure 23: Individual memi mice present different levels of LCMV-specific CD8+ T cells 
upon infection 
Six-week old G3 mice were injected with LCMV and their populations of antigen-specific 
CD8+ T cells (gp33+CD8+) measured at day 8 and day 21 after infection. The experiment 
shown is representative of at least 12 experiments. Here, n = 18 for wt and 9 for memi. 
 
To check whether this altered immune response to viral infection is a consequence of a 
defective development of the immune system, we analysed the cellular composition of the 
peripheral blood (PBL) of naive mice. Interestingly, we observed a dramatic decrease in CD4+ 
T and B220+ B lymphocytes and a significant increase in cells of myeloid origin, such as 
dendritic cells (CD11c+), macrophages (CD11b+) and granulocytes (Gr-1+/Ly-6G+) (fig. 24). It 
seems that the percentage of CD8+ T lymphocytes in the PBL is not affected by the mutation. 
These data show that the memi mutation affects CD8+ T cell primary immune responses to 
LCMV infection and the constitution of the haematopoietic compartment in the blood.  
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Figure 24: Peripheral blood composition of memi mice  
These data is representative of  five independent experiments with at least five mice per 
group. 
 
2. memi is a mutation in deoxycytidine kinase (dCK) 
To identify the causative mutation, we decided to use a classical genetic positional cloning 
approach (Kao et al., 2006). To do so, memi male mice were outcrossed to 129SvlmJ females 
to produce a hybrid generation (H1). H1 littermates were then intercrossed and the H2 
progeny analysed (16 wild types and 5 mutants). These represent 42 meiotic events. The 
mice were analysed for their genotype regarding the 358 single nucleotide polymorphism 
(SNP) of our panel and for their phenotype for CD4+ T cell and B220+ B cell populations in 
the blood. The memi mutation was mapped to a 13.8Mb region on chromosome 5 with a 
logarithm of odds score of 5.01 (fig. 25; LOD score calculation tools obtained from K. Hoebe). 
The region is defined by the SNP 05-078151229-M (LOD score: 3.68), 05-084120220-M (LOD 
score: 5.01) and 05-091950247-M (LOD score: 3.71) which are located at nt 78151229, nt 
84120220 and nt 91950427 on chromosome 5.  
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Figure 25: Whole genome linkage analysis 
The highest LOD score (5.01) was obtained for a 13.8 Mb region on chromosome 5 defined 
by the SNP 05-078151229-M and 05-091950247-M. A total of 21 F2 mice (16 wild-type and 
5 mutants) were used for the analysis. The analysis was performed using LOD score 
calculation tools provided by K. Hoebe (Cicinnati Hopital, USA) 
 
This region contains 84 genes (Ensembl assembly 37) (fig. 26) and the 4 most interesting 
candidate genes are listed (table 8). Among them, the gene encoding deoxycytidine kinase 
was considered a strong candidate based on the T cell phenotype described for the 
complete knock-out mutant (dCK-/-) (Toy et al., 2010). The sequencing of dCK at the genomic 
DNA level in memi mice revealed a single nucleotide transversion (G  T) at nucleotide 739 
of exon 6 (fig. 27). This nucleotide change results in an early translational termination at 
amino acid 246, while the wild-type DCK protein is composed of 260 amino acids (fig. 28). 
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Figure 26: Genes at chromosome 5 in the region between nt 78151229 and nt 91950247 
Red arrows indicate the location of the 3 SNPs on the chromosome (in order from left to right: 
05-078151229-M, 05-084120220-M, 05-091950247-M). The data were obtained and 
modified from Ensembl assembly 37.  
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Gene name Gene 
Start (bp) 
Gene End 
(bp) 
phenotype Reference 
platelet 
factor 4 (PF4)  
91201461 91202407 Homozygous and 
heterozygous null mice 
display increased platelet 
counts and reduced 
thrombus formation 
following vascular injury. 
Thomasset 
et al. 
chemokine 
(C-X-C motif) 
ligand 15 
(CXCL15) 
91223560 91232093 Mice homozygous for a 
targeted null mutation 
are viable and fertile but 
display reduced host 
defense against the 
pulmonary pathogen 
Klebsiella pneumoniae. 
Rossi et al. 
deoxycytidine 
kinase (dCK) 
89194021 89212306 Mice homozygous for 
disruptions in this gene 
have profound defects in 
lymphopoiesis. Thymic T 
cell number and overall 
lymphocyte number are 
greatly reduced. 
Toy et al. 
centromere 
protein C1 
(CENPC) 
86441068 86494496 Homozygous mutation of 
this gene results in early 
embryonic lethality and 
mitotic abnormalities. 
McKay et 
al. 
Table 8: List of candidate genes for the memi mutation  
Information on candidate genes are from the Mouse Genome Informatics database (version 
4.41) 
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Figure 27: The memi mutation is a single nucleotide transversion (G  T) at nucleotide 
739 in exon 6 of dCK 
The bidirectional sequencing of dCK was performed on genomic DNA from dCK+/+ (wt) or 
dCKmem/mem (memi) mice with specific primers. 
 
 
 
Figure 28: The memi mutation results in an early transcriptional truncation of DCK 
protein at amino acid 246 
The memi mutation removes 14 amino acids at the C-terminal end of DCK, including 3 
amino acids from the deoxynucleoside kinase domain.  
 
Wild type DCK contains a deoxynucleoside kinase domain spaning from the 96th amino acid 
to 250th amino acid (fig. 28). Within this kinase domain, DCK contains its ADP and 
nucleoside substrate binding regions (Sabini et al., 2003) (fig. 29). The memi mutation 
removes the last 10 amino acids from its α10-helix.  
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Figure 29: 3D structure of DCK 
The diagram shows only one unit of the DCK dimer. ADP binding region and DCK's natural 
nucleoside substrate dC binding site are indicated. S74 indicates a phosphorylation site of 
DCK for its activity. The location of the memi transversion is indicated by the red arrow and 
affects the last of ten α-helix (obtained and modified from McSorley et al., 2008). 
 
To ensure that the mutation only affects dCK and that no other homozygous mutation is 
found in the 13.8Mb region, we performed a Nimblegen sequence capture technology 
(Roche, UK) and sequenced most exons of our candidate region (performed by P. Mueller). 
First, a standard shot-gun exon library was generated from the whole genomic DNA of memi 
mice and was hybridized to the Sequence Capture array. Target fragments were eluted from 
the array and enriched to be ready for sequencing. This technology allowed us to avoid 
sequencing the whole genome which is cost-inefficient. This approach which gave 98% 
coverage of exons in the region allowed us to confirm that there is only 1 homozygous 
mutation in our candidate region: our memi transversion in dCK (table 9). Herein the rest of 
this thesis, pure wild type mice will be indicated as dCK+/+, memi heterozygous wild type 
littermate as dCKmem/+, homozygous memi mice as dCKmem/mem and dCK knock-out mice (Toy 
et al., 2010) as dCK-/-.  
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# Coverage 
all exons in the region: 
  
191883 nt 100.0% 
covered by sequencing: 
 
179147 bp 98% 
exons with missing coding-information: 3692 bp 2% 
Heterozygous mutations in coding part 
 
12 
 Heteozygous mutations in non-coding part 
 
15 
 Homozygous mutations 
 
1 (dCK) 
Table 9: Results of the Nimblegen targeted sequencing  
With 98% coverage of all exons in the region, it was confirmed that there is only 1 
homozygous mutation exist in the analysed region.  
(the experiment was performed and analysed by P. Mueller) 
 
To further understand the effect of the mutation on dCK, we measured dCK mRNA 
expression levels in dCKmem/+ and dCKmem/mem mice and compared them to that of wild type 
mice (fig. 30; performed by P. Mueller and H. Ghani). We observed that dCKmem/mem mice 
expressed 7 times more dCK mRNA than wild type mice. Moreover, this increased 
expression of dCK mRNA correlated with a higher expression of DCK in memi's spleen (fig. 
31). Taken all together, these results show that our memi mutation enhances the 
transcription and translation of dCK.  
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Figure 30: mRNA expression levels of dCK 
Fold induction of (mRNA)dCK expression in dCKmem/+ compared to dCK+/+ (black bar) and 
dCKmem/mem compared to dCK+/+ (grey bar) splenocytes as measured by RT-PCR. The graph is 
representative of two independent experiments in which (mRNA)dCK expression was 
measured in triplicate with samples from five mice per genotype. 
(Experiment performed by P. Mueller and H. Ghani) 
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Figure 31: DCK expression  
The expression of total DCK was detected in dCKmem/mem and dCKmem/+ splenocytes by 
western blot with a specific anti-DCK antibody. The western blot was repeated at least 3 
times on independent samples from at least 3 independent pooled mice. Actin was used as a 
loading control. 
 
In order to understand the effect of this abnormal translational termination on the protein 
functionality, we measured DCK enzymatic activity in dCK+/+, dCKmem/+, dCKmem/mem mice (fig. 
32; performed by D. Heathcote). To establish the DCK kinase background level in our 
experiment, we used a DCK-deficient cell line (L1210-10K) and its parental cell line (L1210) 
as negative and positive controls, respectively (kindly offered by C. Dumontet (Jordheim et 
al., 2004b). L1210-10K cells were developed by continuously exposure of murine leukemic 
cells line L1210 to increasing concentration of gemcitabine for 3 months. This prolonged 
gemcitabine exposure resulted in a major loss of dCK mRNA expression, probably by 
affecting post-translational modification of DCK or by causing hypermethylation of dCK 
promoter. We found that the DCK activity in dCKmem/mem splenocytes is reduced to the level 
found in L1210-10K cells. We also detected that there is some decrease in DCK enzymatic 
activity in dCKmem/+ heterozygote splenocytes. However, this reduction in activity might not 
have a visible impact, as dCKmem/+ mice present very similar cellular responses to that of wild 
type animals. This result shows that a single nucleotide transversion in dCK causes a DCK 
complete loss-of-function, even though the mutation increases the transcription and 
translation of the gene.  
 
80 
 
L1210 L1210-10K
0
1
2
3
4
5
6
7
8
dCK+/+ dCKmem/+ dCKmem/memen
zy
m
at
ic
 a
ct
iv
ity
 (n
M
/m
in
/µ
g 
of
 to
ta
l p
ro
te
in
)
 
Figure 32: In vitro DCK enzymatic activity assay 
The in vitro DCK enzymatic activity assay was performed using cell lysates from spleens of 
dCKmem/mem , dCKmem/+ and dCK+/+ mice. L1210 and L1210-10K cell-lines were used as 
positive and negative controls, respectively. The graph is representative of two independent 
experiments in which DCK activity was analysed in triplicate with samples pooled from three 
mice per genotype.  
(Experiment performed by D. Heathcote) 
 
3. memi mutation affects lymphocytes development 
The analysis of dCK-/- mice implicated a role for the kinase in T and B cell development (Toy 
et al., 2010). Defects in the peripheral lymphocytes of dCKmem/mem mice were detected with 
and without viral infection. We therefore analysed lymphocytes development in our 
dCKmem/mem mutant. The B cell development in the bone marrow was originally described by 
Hardy et al (Hardy et al., 1991a) (table 10). Depending on the expression of IgM, B220 and 
CD43, B cell developmental stages can be divided into several fractions, corresponding to 
various developmental steps. According to this description, developing B cells undergo BCR 
heavy chain VDJ recombination between fractions B and C. Using these markers, we found 
that dCKmem/mem B cell precursor population lack the Hardy fraction E-F (B220+IgM+) (fig. 33). 
When we further sub-divided the A-D fraction using CD43 expression, we observed that 
most of dCKmem/mem pro-B cells (Hardy fraction A-C; B220+CD43+) seem to be unable to 
proceed to the pre-B cell stage (Hardy fraction D; B220+CD43-).  
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Table 10: B cell developmental stages  
(Summarized from Hardy et al., 1991) 
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Figure 33: B cell development in dCKmem/mem mice 
Flow cytometric analysis of B-cell development in dCKmem/mem and dCKmem/+ bone marrow. 
Hardy fractions E-F (B220+IgM+) and A-D (B220+IgM-) are represented in the left panels and 
immature B cells (A-D) are further distinguished into fractions A-C (pro-B; CD43+) and D 
(pre-B; CD43-) in the right panels. The flow cytometry dot plots are from two representative 
mice, and the graphs are representative of two independent experiments with five mice per 
genotype each. 
 
We also observed an abnormal T cell development in the mutant. dCKmem/mem thymi were 
found to be reduced in size and cellularity as compared to wild type controls (fig. 34). When 
a T cell haematopoietic precursor enters the thymus, it undergoes several developmental 
steps which can be distinguished by the expression of surface markers such as CD4, CD8, 
CD44 and CD25 (fig. 35). In the beginning, it does not express any CD4 or CD8 and is 
therefore called double negative (DN). DN cells can be further divided into 4 sub-stages by 
looking at the expression of CD44 and CD25. DN1 are CD25-CCD44+, DN2 are CD25+CD44+, 
DN3 are CD25+CD44- and DN4 are CD25-CD44-. Once a developing T cell reaches the double 
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positive stage (DP), it expresses CD4 and CD8 simultaneously and then finally becomes a 
mature T cell by differentiating into either CD4 or CD8 single positive (SP) cell.  
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Figure 34: dCKmem/mem mice have reduced thymic size and cellularity 
Thymi of two representative mice are indicated by the blue lines and cells were counted with 
an automatic cell counter. The graph is a combination of three independent experiments with 
at least three mice per group. In this graph, the error bars represent standard error of the mean 
(SEM). 
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Figure 35: T cell developmental stages  
(Modified from Anderson and Jenkinson 2001) 
 
When we analysed memi thymocyte development, we observed a great reduction in DP 
cells and a consequent decrease in SP cells in dCKmem/mem mice (fig. 36). We then analysed 
DN population by excluding lineage positive cells (B220+ or Ter-119+ or CD11b+ or NK1.1+) to 
prevent any possible interference of cells from non-T cell lineage. By doing so, we noticed 
that there was a developmental blockage between the DN3 and DN4 stages (fig. 36). It is at 
the DN3 stage that developing thymocytes undergo TCRβ gene rearrangement to finally 
express the pre-TCR complex on the surface (Saint-Ruf et al., 1994). In addition, we have just 
shown that memi's B cell developmental is impaired at the fraction C, where BCR heavy 
chain VDJ recombination occurs. We therefore questioned, as it had been proposed in the 
article describing the dCK-/- mice, whether DCK is involved in V(D)J recombination. To do so, 
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we tested the intra- and extra-cellular expression of the TCRβ chain in the DN3 and DN4 
populations. We observed an increase in intra-cellular TCRβ expression and no difference in 
extra-cellular TCRβ expression (fig. 37), suggesting that TCRβ rearrangement might not be 
affected by the absence of functional DCK. 
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Figure 36: dCKmem/mem T cells development is blocked at the transition between the DN3 
and DN4 stages  
B220+, CD11b+, Ter-119+, NK1.1+ cells were gated out and the DN population was defined 
on the CD4-CD8 histogram. The flow cytometry dot plots are from two representative mice 
and the graphs are representative of three independent experiments with five mice per 
genotype each. 
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Figure 37: Intracellular expression of TCRβ in the DN3 thymocytes (left) and 
extracellular expression of TCRβ in the DN4 mutant thymocytes (right) 
Linage positive cells (B220+, Ter-119+, NK1.1+, CD11b+) were gated out for the analysis. 
n=5 for each genotype.  
 
If V(D)J rearrangement in the TCRβ chain is not affected in memi cells, we could hypothesise 
that the DN3 developmental defect can be due to a pre-TCR signalling problem. Mice which 
are reported to have pre-TCR signalling defects, for example pre-TCRα-/- mice, commonly 
display a higher expression of CD25 (IL-2 receptor α chain) at DN3 (Laurent et al., 2004). 
Their TCRβ chain formation does not seem to be affected (Saint-Ruf et al., 1994). We 
therefore measured the mean fluorescent intensity (MFI) of CD25 expression on memi DN3 
thymocytes (fig. 38) and observed a significant increase in CD25 expression levels. We 
therefore suspect that dCKmem/mem mice might have pre-TCR signalling problems.  
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Figure 38: CD25 expression on DN3 cells 
The mean fluorescence intensity (MFI) obtained for CD25 expression on the DN3 population 
is indicated. These data are representative of three independent experiments with at least five 
mice per group each. 
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4. memi mutation affects splenic size and composition 
Uninfected dCKmem/mem mice present a dramatic increase in splenic size and splenic/total 
body weight ratio (fig. 39). This phenotype is thought to be due to the significant expansion 
of non-lymphoid cells such as erythroid progenitor cells (Ter-119+) (Ikuta et al., 1990), 
CD11c+ dendritic cells (CD11c+) (Robinson et al., 1999), macrophages (CD11b+) (Robinson et 
al., 1999) and granulocytes (Gr-1+) (Spangrude et al., 1988) (fig. 40). On the contrary, CD4+ T 
and B220+ B lymphocytes were significantly reduced in the spleen, which correlates with 
what we observe in the peripheral blood (fig. 24). For the rest of my work on memi, we 
decided to focus on peripheral T cells. 
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Figure 39: dCKmem/mem mice present a significant splenomegaly  
Spleens from dCKmem/mem (upper) and dCK+/+ (lower) mice. The relative spleen weights were 
obtained by dividing the spleen weight by the total body weight of individual mice. n=5 for 
each genotype. 
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Figure 40: Splenomegaly of dCKmem/mem mice seems to be due to an increase in non-
lymphoid cells 
Spleen composition in dCKmem/mem and dCK+/+ mice. The absolute cell-number of each 
population was calculated from flow cytometry data. This graph is representative of three 
independent experiments with at least three mice per genotype. n=4 for wild type mice and 
n=5 for memi mice.  
 
5. memi mutation facilitates peripheral lymphocyte proliferation 
During LCMV infections, dCKmem/mem mice presented high percentages of KLRG-1 expressing 
cells on expanding Ag-CTL, which indicates that they underwent more than 10 rounds of cell 
division. In addition, some mice showed a great increase in their CTL population. This led us 
to investigate the ability of lymphocytes to proliferate. To do so, naive mice were given 
BrdU-containing water for 8 days, and we measured the percentage of BrdU incorporating 
lymphocytes in their spleen. We found that both dCKmem/mem CD4+ and CD8+ T lymphocytes 
incorporated higher amounts of BrdU, with a higher significant difference for CD4+ T 
lymphocytes (fig. 41). This result correlates with an increased expression of Ki-67, a marker 
of all non-quiescent cells (Gerdes et al., 1984b) in CD4+ and CD8+ T lymphocytes (fig. 42). 
These results show that dCKmem/mem lymphocytes are hyper-proliferative. 
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Figure 41: dCKmem/mem CD4+ and CD8+ T cells incorporate more BrdU than dCKmem/+ 
cells 
Representative flow cytometry plots and histograms are shown for CD4+ and CD8+ T cells 
(bottom left: %cells, bottom right: absolute cell numbers). Each experiment was done three 
times independently with at least three mice per genotype. 
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Figure 42: CD4+ and CD8+ T splenocytes in dCKmem/mem mice are highly proliferative as 
indicated by Ki-67 expression 
Representative flow cytometry plots and histograms are shown for CD4+ T cells (left) and 
CD8+ T cells (right). Ki-67 expression (red line) was measured by subtracting the expression 
of the isotype controls (green line). The graph is a combination of 5 independent experiments 
with at least three mice per genotype.  
 
As memi's increased proliferation is observed without any treatment or the presence of 
foreign antigens, we suspected that the high level of proliferation could be due to 
homeostatic proliferation. To confirm this idea, we stained memi's PBL with the activation 
marker CD44 and the homing marker CD62L (Murali-Krishna and Ahmed, 2000) (fig. 43). 
memi mice presented increased percentages of CD44+ and decreased percentages of CD62L+ 
cells in their CD4+ T population, which indicates that dCKmem/mem lymphocytes present similar 
marker expression patterns to cells undergoing homeostatic proliferation.  
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Figure 43: Expression of the activation and maturation marker CD44 and of the 
adhesion molecule CD62L on mutant and wild type peripheral blood CD4+ T cells 
These data are representative of three independent experiments performed on at least three 
mice each. 
 
To dissect this hyper-proliferation phenotype in more details, cell cycle progression was 
analysed in splenocytes ex vivo by an anti-BrdU and 7-AAD co-staining. Unsurprisingly, we 
found a significant increase in S phase cells and a relative decrease in G0/G1 phase resting 
cells in the CD4+ T lymphocyte population (fig. 44). There was no significant difference in 
G2/M phase cell population between dCKmem/+ and dCKmem/mem splenocytes. In contrast, 
mutant CD8+ T lymphocytes did not show any notable difference in their cell cycle 
progression pattern as compared to that of wild type controls. 
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Figure 44: Cell-cycle analysis of T lymphocytes using a BrdU/7-AAD staining 
Populations were defined by flow cytometric analysis. Upper graph indicates %cells and 
lower graph indicates absolute cell numbers. This data represents three independent 
experiments with five mice per genotype. 
 
As we observed an accumulation of S phase splenocytes in dCKmem/mem mice, we were 
curious about the expression status positive and negative regulators of the cell cycle. We 
therefore analysed the expression of cyclin A and cyclin D3, which promote S phase 
progression, retinoblastoma (pRb), which inhibits S phase entry of cells by forming pRb-E2F 
complex in G0/G1 phase (Cobrinik, 2005), and p27Kip1, which inhibits cyclin D and A 
(Toyoshima and Hunter, 1994). This was done by western blot on whole spleen extracts 
from dCK+/+, dCKmem/+ and dCKmem/mem mice (fig. 45; performed by K. Ho). As expected, we 
found that the expression of both cyclin D3 and A is elevated and the expression of pRb and 
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p27Kip1, is nearly undetectable in dCKmem/mem mice. To exclude any impact that the increased 
ratio of myeloid cells could have on this analysis, we analysed the same proteins on extracts 
from combined inguinal and mesenteric lymph nodes. Even though the intensity of protein 
expression was relatively low, similar results were obtained.  
 
 
Figure 45: Expression pattern of cell cycle regulators in dCKmem/mem mice 
Western blot was done with samples from spleen or inguinal lymph nodes from the following 
genotypes: dCK+/+, dCKmem/+, and dCKmem/mem. The experiment was done twice independently 
with pooled samples of three mice per genotype and per organ. Actin was used as a loading 
control. (Experiment performed by K.K. Ho) 
 
The reduced expression of p27Kip1 led us to test the expression of Foxo3a (FKHRL1), a 
transcriptional activator of p27Kip1 (Medema et al., 2000).We could detect significantly less 
Foxo3a in the spleen protein extracts from dCKmem/mem mice as compared to wild type and 
wild type littermate controls (fig. 46). All these data show that the hyper-proliferation in 
dCKmem/mem mice is supported by an enhanced expression of S phase promoting cyclins and a 
constitutive inhibition of their negative regulators.  
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Figure 46: Expression levels of Foxo3a in samples from dCK+/+, dCKmem/+, and 
dCKmem/mem spleens 
The experiment was done twice independently with pooled samples of three mice per 
genotype and per organ. Actin was used as a loading control. 
 
6. memi and the intracellular signalling pathways 
Our observation of a dramatic inhibition of Foxo3a in dCKmem/mem splenocytes implicated the 
possibility that DCK might be interefering with intracellular signalling pathways which 
control Foxo3a expression. Since Akt and ERK are known to be negative regulators of Foxo3a 
(Biggs et al., 1999; Davis et al., 2009), we first investigated the expression levels of some 
signalling molecules in the PI3K/Akt and the JAK/MAPK/ERK pathways in the spleen (fig. 47). 
PI3K activates Phosphoinositide dependent kinase 1 (PDK1) to activate Akt, while PTEN 
inhibits PDK1. We did not detect a major difference in PDK1 and PTEN expression levels 
between dCKmem/+ and dCKmem/mem splenocytes. In contrast, we detected a reduced 
expression of STAT5 which is a downstream molecule of JAK. However, we could not find 
any notable difference in the expression of ERK 1/2 (p44/p42 MAPK) and p38 which is an 
inhibitor of Foxo3a. Surprisingly, when we did the same analysis with cells from lymph 
nodes, we found a great increase in the expression of the phosphorylated from of p38 
(active form) (fig. 48). Altogether, these data imply that DCK deficiency might influence the 
p38-Foxo3a pathway. However, we also have to investigate more signalling molecules in 
other pathways such as Akt and PI3K.  
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Figure 47: Expression pattern of signalling molecules in dCKmem/mem splenocytes 
The protein analysis was done by western blot with samples from dCKmem/+, and dCKmem/mem 
spleens. The experiment was done once with pooled samples of three mice per genotype and 
per organ. Actin was used as a loading control.  
 
 
Figure 48: Expression pattern of phosphorylated-p38 in dCKmem/mem mice 
Western blot was done with samples from mesenteric and inguinal lymph nodes from 
dCKmem/+, and dCKmem/mem mice. The experiment was done with pooled samples of three mice 
per genotype and per organ. Actin was used as a loading control.  
 
8. memi mutation promotes cell death in the periphery 
The following reasons lead us to investigate apoptosis in memi's peripheral lymphocyte: 
1/ memi mice have far less peripheral lymphocytes as compared to wild type controls even 
though they are hyper-proliferative (fig40, 41 and 42).  
2/ Foxo3a is known to regulate cell cycling check-point by repressing G1-S phase progression 
inducer D type cyclins (Schmidt et al., 2002), and an inappropriate check-point control can 
cause cell death. Since we observed downregulation of Foxo3a expression in dCKmem/mem 
splenocytes (fig. 46), we suspected memi's lymphocytes could be prone to cell death.  
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3/ While IL-2 acts as a proliferation and surviving factor to healthy wild type lymphocytes, it 
can induce cell death to apoptosis-prone cells (Lenardo, 1991). Upon IL-2 stimulation, we 
found that dCKmem/mem lymphocytes had a low viability which implicates they might be 
susceptible to apoptosis.  
We therefore measured cell death in dCKmem/mem lymphocytes by staining them with 
Annexin V. AnnexinV marks extracellular phospatidyl serine (PS), an indicator of apoptosis 
(Koopman et al., 1994) (fig. 49). Without any external death stimulus, the expression of PS 
was significantly increased in both CD4+ and CD8+ T dCKmem/mem lymphocytes.  
Since Annexin V is also known to drive cell migration (Nakao et al., 1994), we decided to 
confirm that this high Annexin V staining was apoptosis by measuring the population of 
early apoptotic Yopro-1+ lymphocytes (fig. 50). We observed more Yopro-1+ cells in memi 
mice than wild type mice and CD4+ T lymphocyte cell death seems to be more affected than 
death of CD8+ T lymphocytes. Finally, the staining of lymphocytse with an anti-active 
caspase-3 antibody shows that the elevated cell death in dCKmem/mem lymphocytes is caspase 
3-dependent (fig. 51).  
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Figure 49: Annexin-V expression in CD4+ and CD8+ T cells 
The flow cytometry histogram is from CD4+ (left) and CD8+ T cells (right) from two 
representative mice and the graph is the combination of three independent experiments with 
at least three mice per group each. 
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Figure 50: Increased apoptosis in dCKmem/mem mice as indicated by increased Yopro-1 
incorporation 
The flow cytometry dot plot represents Yopro-1 expressing CD4+ T cells. The experiment 
was done once with five mice per genotype.  
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Figure 51: Active caspase-3 expression in CD4+ and CD8+ T cells 
The flow cytometry plots are from CD4+ (left) and CD8+ (right) T cells from two 
representative mice. The graph is representative of two independent experiments with five 
mice per genotype each.  
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9. memi mutation causes homeostatic proliferation by cell-intrinsic and –extrinsic 
mechanisms 
In the absence of any specific stimulation, dCKmem/mem lymphocytes present increased levels 
of proliferation and of cell death. These phenotypes can be due to a cell-intrinsic and/or -
extrinsic effect of the memi mutation.  
1/ If proliferation and apoptosis are controlled by cell-intrinsic mechanism, dCKmem/mem 
lymphocytes will always be hyper-proliferative and prone to apoptosis regardless of their 
surroundings. On the other hand, wild type lymphocytes, if placed in a memi mutant 
environment, will not proliferate or die but remain quiescent. 
2/ If proliferation and apoptosis are controlled by cell-extrinsic mechanisms, memi 
lymphocytes placed in a wild type environment will stop proliferating and dying, while wild 
type lymphocytes placed in a DCK-deficient environment will start to proliferate and die.  
 
To address this intrinsic/extrinsic question, we adoptively transferred purified 
Thy1.2;dCKmem/mem CD4+ T lymphocytes to Thy1.1;dCK+/+ non-irradiated congenic recipients 
or Thy1.1;dCK+/+ CD4+ T lymphocytes to Thy1.2;dCKmem/mem non-irradiated recipients (fig. 52). 
At regular intervals, donor and endogeneous cells were analysed in the blood of recipient 
mice.  
 
 
Figure 52: Cross-adoptive transfer experiment 
Thy1.1;dCK+/+ wild type CD4+ T donor cells were injected into Thy1.2;dCKmem/mem recipients 
and vice versa. 
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In the Thy1.2;dCKmem/mem recipient environment, we found that the percentages of donor 
Thy1.1;dCK+/+ CD4+ T lymphocytes increased over time (fig. 53). In addition, as soon as 6 
days after the transfer, we found that these cells changed from a naive phenotype 
(CD44loCD62Lhi) to an effector memory-like phenotype (CD44hiCD62Llo) (fig. 54). These data 
support a model of homeostatic proliferation for the wild type donor in the host DCK-
deficient environment.  
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Figure 53: Time course for donor cells in their host environments  
The percentage of donor cells was defined as a percentage of total CD4+ T cells in the 
recipients. Thy1.1;dCK+/+ donor cells in the memi recipient CD4+ compartment are in black 
and the Thy1.2;dCKmem/mem donor cells in the wild type recipient in grey. 
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Figure 54: the dCK-deficient environment induces a memory-like phenotype in wild 
type donor cells 
The expression of CD44 (top graph) and of CD62L (bottom graph) were measured on the 
Thy1.1;dCK+/+ (black lines) and Thy1.2;dCKmem/mem (grey line) donor CD4+ T cells only at 
various time points in the blood of recipients. 
 
As a direct measure of proliferation, splenocytes were stained with Ki-67 35 days after 
transfer (fig. 55). In the Thy1.2;dCKmem/mem host, Thy1.1;dCK+/+ donor cells proliferated 
significantly more (first column of the graph) than wild type endogenous cells (last column). 
These three data demonstrate that the DCK-deficient environment promotes cell 
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proliferation of wild type cells. Finally, we measured the expression of Annexin V on 
Thy1.1;dCK+/+ donor cells (fig. 56). We found a significant increase in apoptotic cells in 
Thy1.1;dCK+/+ donor population (first column) which is comparable to that of memi 
endogenous cells (second column). Taken together, we hypothesise that the memi’s DCK-
deficient lymphopenic environment induces proliferation and cell death of wild type cells. 
This would indicate the cell-extrinsic effect of the mutation on lymphocyte proliferation and 
apoptosis.  
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Figure 55: Ki-67 expression in donor and host cells was measured in splenocytes 35 days 
after transfer 
Ki-67 expression was measured by subtracting the expression of the isotype controls in each 
individual sample. The first two columns indicate donor and  endogenous cells in the memi 
hosts, the last two columns indicate donor and endogenous cellsin the wild type hosts. This 
figure is representative of two separate experiments with five recipients per group. 
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Figure 56: Apoptosis of donor and recipient cells was measured with an anti-Annexin V 
antibody in splenocytes 35 days after transfer 
The first two columns indicate donor and  endogenous cells in the memi hosts, the last two 
columns indicate donor and  endogenous cells in the wild type hosts. This figure is 
representative of two separate experiments with five recipients per group. 
 
When we tracked the behaviour of Thy1.2;dCKmem/mem donor cells in Thy1.1;dCK+/+ recipients, 
we detected that the number of donor CD4+ T lymphocytes did not expand in the wild type 
environment (fig. 53). This could be due to either the cells proliferating and dying at the 
same rate or becoming quiescent. To understand their behaviour in the wild type 
environment, we observed that Thy1.2;dCKmem/mem donor cells conserved their memory-like 
phenotype (CD44hiCD62Llo) for 28 days post-adoptive transfer (fig. 54). This observation 
suggests that Thy1.2;dCKmem/mem donor CD4+ T cells have not reverted to quiescence. 
Therefore, the Thy1.2;dCKmem/mem donor cells might proliferate and die at the same rate 
than if they were in a DCK-deficient environment. Indeed, we confirmed this by analysing 
memi donor cells and wild type recipient endogenous cells with Ki-67 and Annexin V at day 
35 post-adoptive transfer. First, as shown in figure 54, the proliferation capacity of 
Thy1.2;dCKmem/mem donor cells (third column of the graph) did not seem to be affected by 
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the wild type host environment as they showed significantly high levels of proliferation 
compared to Thy1.1;dCK+/+ endogenous cells (fourth column). In addition, their proliferation 
capacity is comparable to memi endogenous cells (second column). Second, we measured 
the percentages of early apoptotic cells by Annexin V staining (fig. 56). Thy1.2;dCKmem/mem 
donor cells (third column), again, showed significantly higher Annexin V+ cells than their 
host endogenous cells (the fourth column). These observations imply that the memi 
mutation could affect cell proliferation and apoptosis in a cell-intrinsic manner. All together, 
these results seem to support a model in which a deficiency in DCK could drive proliferation 
and cell death in both intrinsic and extrinsic manners.   
 
To study the cell-intrinsic effect of memi mutation further, 1:1 mixture of Thy1.2;dCKmem/mem 
and Thy1.1;dCK+/+ bone marrow cells into lethally irradiated recipient Thy1.1;dCK+/+ mice to 
generate chimeric mice (fig. 57). Five weeks after injection, the recipients were analysed for 
their thymic development, peripheral proliferation and apoptosis.  
 
 
Figure 57: 1:1 chimera experiment 
Lethally irradiated Thy1.1;dCK+/+ recipients were injected 1:1 mixture of Thy1.2;dCKmem/mem 
and Thy1.1;dCK+/+ bone marrow cells.  
 
In the thymus, we found that Thy1.2+ thymocytes which were originated from 
Thy1.2;dCKmem/mem donors were very little in numbers and composed only 5% of the 
recipient's thymus (table 11). They still demonstrated the similar DN3 to DN4 
developmental blockage that we observed in memi mice (fig. 58) and Thy1.2+ splenocytes 
were hyper-proliferative and hyper-apoptotic in the periphery (fig. 59). All these result 
emphasized that the memi mutation affects lymphocyte development and their peripheral 
behaviour in cell-intrinsic manner.   
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Table 11: Thy1.2+ thymocyte numbers and ratio to Thy1.1+ thymocytes in 1:1 chimera 
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Figure 58: Thy1.2;dCKmem/mem thymocytes presented developmental blockage between 
DN3 and DN4 stages in wild type environment 
By gating on either Thy1.1+ wild type or Thy1.2+ memi, thymocytes were analyzed in the 
recipient mice for their DN cells distribution. The histograms are from 2 representative mice 
and the graph representative of 2 independent experiments with at least 4 mice per group.  
 
 
105 cells Thy1.2+ cell number Whole thymic cell count Thy1.2+/Thy1.1+
recipient 1 19 374 0.05
recipient 2 24 407 0.06
recipient 3 21 352 0.06
recipient 4 14 278 0.05
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Figure 59: Highly proliferative and apoptotic Thy1.2;dCKmem/mem lymphocytes in the 
periphery of 1:1 chimeric recipients 
Proliferation and apoptosis were analyzed by gating splenic lymphocytes for either Thy1.1+ 
wild type or Thy1.2+ memi and measuring Ki-67 or Annexin V expression, respectively. The 
graphs are representative of 2 independent experiments with at least 4 mice per group. 
 
Discussion 
 
The memi mutation was isolated after screening 727 mice with LCMV Armstrong. The 
mutation causes a single nucleotide change in exon 6 of the gene encoding DCK, a crucial 
enzyme of the nucleoside salvage pathway. As a result, the functionality of DCK is abolished. 
A knockout allele in dCK had been already published by another group and we could observe 
similar phenotypes in our null mutant. However, we also observed characteristics that had 
not been described before. In our study of lymphopoesis, we observed that memi mutants 
present similar developmental defects than the dCK-/- knock-out mice. In addition, we could 
establish for the first time the importance of DCK in controlling homeostatic proliferation 
and survival of T lymphocytes in the periphery. Finally, we also found a great increase of the 
myeloid cell population in memi’s spleen, which could be studied further to understand the 
mechanisms controlling myeloproliferation.  
 
1. dCK positional cloning  
Outcrossing memi mutant mice with a different inbred strain and performing a positional 
cloning approach using SNPs to calculate a LOD score is a common method to genotype 
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ENU-induced mutations. Usually, a LOD score of 3 or more is considered significant and a 
LOD score higher than 5 is considered a very strong linkage (Barbaric et al., 2008; Crozat et 
al., 2007). Our high LOD score, therefore, guaranteed that the memi mutation lied within 
the 13.8Mb region on chromosome 5. This region contains 84 genes and pseudogenes 
which was a number small enough to look at the literature and sequence the most probable 
candidates. In our case, dCK was the strongest one based on the previously reported KO 
phenotype (Toy et al., 2010). Sequencing of dCK in memi mice revealed a point mutation in 
exon 6, which impact on DCK functionality was later confirmed by enzymatic assay. To 
eliminate any possibility that more than one mutation in the 13.8Mb region participated in 
the observed phenotype, we performed a Nimblegen sequence capture analysis (Roche, UK) 
and found that the transversion in dCK was the only homozygous mutation affecting exonic 
sequences in the region. With all these data, we are confident that the memi mutation is a 
dCK null point mutation. Other methods to confirm that dCK is the only mutated gene in our 
mice would be to generate bone marrow chimera with cells that express a wild type copy of 
dCK to rescue the memi phenotype or to perform a complimentation test by crossing memi 
mice with the dCK KO mice.  
 
2. The impact of dCK mutation on the protein function and dCK mRNA levels 
To date, most of structural studies on DCK focus on the kinase domain (96th amino acid to 
250th amino acid) which contains various substrate binding sites (reviewed in Sabini et al., 
2003). However, the memi mutation in dCK emphasizes the importance of the last 14 amino 
acids at the C-terminal end of the protein in terms of its enzymatic activity. Two scenarios 
are possible to explain the reduction in memi's DCK enzymatic activity: the substrate binding 
sites are disturbed, or the enzyme itself is transformed into an inefficient conformation. The 
former case seems to be less compelling, as none of reported substrate binds to the 247th 
to 250th amino acid section of DCK. Then, the later hypothesis could be more convincing. As 
DCK acts as a homodimer, the lack of 14 amino acids might affect the overall conformation 
of the protein and eventually could interrupt its dimerization. To check memi's DCK 
dimerization ability, non-denaturating native polyacrylamide gel electrophoresis (PAGE) 
could be performed.  
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To explain the increase in mRNA and protein levels in dCK deficient splenocytes, we can 
hypothesise the existence of a negative feedback loop in which the functional protein 
negatively regulates the production of its own mRNA. In the case of memi cells, this negative 
feedback loop would not work properly as memi's DCK is not functional. As a result, the 
mRNA and DCK protein would increase. This could be confirmed by supplying sufficient wild 
type DCK to memi splenocytes and measuring their change in dCK mRNA expression levels.  
 
3. Lymphocyte development in memi mice 
The memi mutation causes B and T cell population defects by arresting their development at 
the Hardy fraction C and the DN3 stages, respectively. The relevance between dCK mutation 
and lymphocyte developmental defects has only recently been reported (Toy et al., 2010). 
Our finding with dCKmem/mem mice enhances this role of DCK in lymphocyte development.  
 
3.1. B cell development in memi mice 
In the bone marrow, about 0.02% of hematopoietic stem cells differentiate into common 
lymphoid progenitor (CLP) (Ollila and Vihinen, 2005) of which some will further develop into 
mature B cells. When CLPs lose their pluripotency and develop into a pro-B cells 
(B220+CD43+; Hardy fractions A-C) and further into pre-B cells (B220+CD43-; Hardy fraction D) 
(Hardy et al., 1991b), they undergo somatic B cell receptor (BCR) recombination, which is 
crucial to enable B cells to recognize various antigens (reviewed in Ollilia and Vihinen (Ollila 
and Vihinen, 2005), and Jung and Alt (Jung and Alt, 2004)). At the early pro-B cell stage 
(Hardy fractions A and B), immunoglobulin heavy chain Diversity (D) and Joining (J) segment 
gene rearrangement takes place and cells become late pro-B cells (Hardy fraction C). This is 
followed by the Variable (V) chain rearrangement to the DJ sequence and the cells 
becoming pre-B cells (Hardy fraction D) (Martensson et al., 2010). Then pre-B cells 
transiently express the pre-BCR which is capable of transmitting essential developmental 
signals, including down-regulating recombination-activating (RAG) genes and inducing 
proliferation (Martensson et al., 2010). When immature B cells successfully pass these 
developmental checkpoints and selection processes, they become mature B cells, which will 
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migrate to secondary lymphoid organs and remain quiescent until their activation by 
antigen recognition. 
 
3.2 T cell development in memi mice 
In the case of thymocytes, early DN thymic progenitor cells which lack the expression of 
either CD4 or CD8 molecules migrate from the bone marrow to the thymus where they 
differentiate into mature T cells. DN thymocytes can be further distinguished by the surface 
expression of CD44, CD25 and CD117 (c-kit) (Michie and Zuniga-Pflucker, 2002). At the DN3 
stage, a similar V(D)J recombination as in B-cells takes place and allows pro-T cells to 
express the TCR-β chain. This chain then associates with the pre-Tα chain and CD3 to form 
the pre-TCR complex (Jung and Alt, 2004). These cells will proceed to the DP stage at which 
they will face positive selection. Only DP cells which recognize self-MHC molecules will then 
undergo negative selection to eliminate cells which have a strong avidity for self-peptide 
and prevent autoimmunity. DP cells which pass these selection processes subsequently 
become SP mature T cells then migrate to secondary lymphoid organs. However, if 
developing DN3 thymocytes fail to undergo a successful TCR-β chain rearrangement, they 
will be removed from the pool by β selection, the process that eliminates thymocytes which 
did not undergo successful TCR-β chain formation (Mallick et al., 1993).  
During V(D)J segment recombination, double stranded DNA (dsDNA) is cleaved by the RAG 
complex (Oettinger et al., 1990).The broken ends are then joined by the non-homologous 
DNA end joining (NHEJ) machinery (Roth, 2003). This complex process is carefully controlled, 
yet, inevitably requires an efficient DNA repair machinery to correct errors which can 
potentially cause severe DNA damages. Imbalance of the dNTP pool has been shown to 
disrupt DNA repair, as for example the accumulation of dATP or deoxyadenosine interferes 
with the repair machinery (Cohen and Thompson, 1986; Seto et al., 1986). In addition, a 
dNTP inbalance can influence the frequency of V(D)J recombination and might affect the 
diversity of antigen receptors (Gangi-Peterson et al., 1999).  
 
 
 
110 
 
3.2.1 Cell-intrinsic T cell development defect by pre-TCR signalling 
From 1:1 chimera study, we found that the memi mutation affects thymic development in 
cell-intrinsic manner (fig. 58). Toy et al. (Toy et al., 2010) proposed a hypothesis to explain 
the abnormal T cell development observed in their dCK-/- mutants. They suspected that 
insufficient dNTP supply due to DCK deficiency would not be able to support the 
proliferation of DN3 thymocytes by creating a "bottleneck" effect. However, even if we have 
not measured proliferation in our DN3 and DN4 mutant thymocytes, we observed an 
increased lymphocyte proliferation capacity in the periphery (fig. 41 and 42) and upon viral 
infection (fig. 21). This could indicate that DCK-deficient thymocytes could have the 
potential to proliferate extensively, which can be tested by measuring BrdU incorporation in 
memi thymocytes. At the same time, we could measure wild type levels of intra- and extra-
cellular TCR-β expression in dCKmem/mem DN3 thymocytes (fig. 37) which implies that their 
V(D)J recombination might not be affected. Instead of V(D)J recombination, we suspect that 
the TCR signalling pathway might be affected by the absence of functional DCK. This is 
because we observed an increased CD25 expression in DN3 dCKmem/mem thymocytes (fig. 38), 
which is a common phenotype in animals with defective pre-TCR signalling (Laurent et al., 
2004). In the same study, TCR-α-/- DN3 and DN4 thymocytes showed less BrdU incorporation 
due to disrupted pre-TCR signalling. Therefore, to investigate whether memi thymocytes 
suffer from the same problem, we could measure their proliferation capacity by BrdU. 
Furthermore, we could investigate the activation of intracellular signalling molecules for 
pre-TCR signalling, such as as Src family tyrosine kinase Lck and Fyn (Groves et al., 1996), Syk 
family kinase Zap-70 and Syk (Cheng et al., 1997) and their downstream adaptor proteins 
SLP-76 and PLCγ (Yoder et al., 2001).  
 
Another factor which might affect pre-TCR signalling in dCKmem/mem thymocyte development 
could be a dNTP imbalance caused by DCK functionality defect. For example, when 
adenosine deaminase (ADA), an enzyme which irreversibly converts adenosine and 2'-
deoxyadenosine into inosine and 2'-deoxyinodine is absent, developing thymocytes cannot 
survive through β-selection, even though their TCR-β chain rearrangement and pre-TCRα 
expression are not affected (Thompson et al., 2000). It is thought that the accumulation of 
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ADA substrate would induce leakage of cytochrome-c from the mitochondria and would 
participate in apoptosome formation, therefore induce subsequent apoptosis. In addition, 
ADA-deficient T cells demonstrate an impaired TCR activation and signalling both in in vivo 
and ex vivo conditions (Apasov et al., 2000; Apasov et al., 2001). Since deoxyadenosine is 
one of DCK substrate, we could hypothesise that memi's lymphocyte development is 
affected in a similar manner: the reduction in DCK activity could result in the accumulation 
of DCK substrates such as deoxyadenosine and its derivatives and could interfere with the 
TCR signalling pathway. To test if the TCR signalling in memi thymocytes is impaired by a 
similar mechanism as in ADA-deficient mice, we could measure TCR activation markers CD25 
and CD69 after injecting an anti-TCR/CD3 antibody in the presence of DCK substrates 
(Muraro et al., 2005).  
 
3.2.2 Possible DCK interaction with pre-TCR signalling molecules 
Although the pathway is not fully understood yet, several reports suggest the possible 
involvement of the PI3K/Akt signalling pathway in response to multiple survival signals 
during β-selection at the DN3 stage (reviewed in Juntilla and Koretzky (Juntilla and Koretzky, 
2008)). Upon Notch (Ciofani and Zuniga-Pflucker, 2005), IL-7 (Akashi et al., 1997) or pre-TCR 
stimulation (Wurch et al., 1999), the phosphatidylinositol 3-kinase (PI3K) cascade is 
activated and conveys cell proliferation signals. Inhibition of PI3K in human thymocytes 
results in a reduced activation of MEK and ERK upon TCR stimulation (Fung et al., 2003), 
suggesting the existence of a cross-talk between the PI3K/Akt pathway and MEK/ERK. As 
ERK plays an important role in transmitting pre-TCR signals during β-selection of DN cells (Xu 
et al., 2009), we could first investigate the relationship between DCK and PI3K/Akt or 
MEK/ERK signalling molecules. In addition, transgenic mice which have constitutive 
activation of MKK6-p38 pathway present similar phenotypes to memi mice, such as 
thymocyte developmental blockage at the DN3 stage and increased S phase population 
(Diehl et al., 2000), which suggests that the MKK6-p38 signalling pathway could also be a 
very good target to investigate. 
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Although memi mice suffer from severe T cell development defects, some thymocytes 
survive development, become single positive T lymphocytes and migrate to the periphery. 
Upon LCMV Armstrong infection, some memi mice presented a significant expansion of 
gp33+ CD8+ T cells while other memi mice did not show any gp33 CTL expansion (fig. 23). 
One possible reason to explain these individual differences could be that in some mice, CD8+ 
T cells specific for gp33 survive development, migrate to the periphery where they will 
expand after infection. In some other mice, gp33 specific precursors will not survive 
development and these mice will therefore be devoid of this particular Ag specific response 
in the periphery. CD8+ T cell pool in memi mice might be therefore composed of T cells with 
very limited TCR repertoire. To test this hypothesis, we could perform a CDR3/TCR 
spectratyping (Memon et al., 2011) with memi's LCMV-specific CD8+ T cells and compare 
memi's TCR repertoire with that of wild type mice .  
 
4. Peripheral lymphocyte and myeloid cell proliferation 
BrdU is a synthetic nucleoside which is incorporated into DNA of proliferating cells. At a 
given condition, if a cell divides more than the others its BrdU incorporation will be higher 
as it has to undergo more DNA replication and takes more BrdU. Therefore, it is generally 
accepted that a high degree of BrdU incorporation indicates cell proliferation. However, 
when lymphocytes are prone to apoptosis due to a mutation, it would be debatable that 
existing lymphocytes would incorporate more BrdU to support high turnover to maintain 
their numbers than to actually increase the size of the population. To clarify that memi's 
lymphocytes are indeed proliferating, we also measured the absolute cell numbers of BrdU 
incorporating lymphocytes. We found a significant increase of BrdU incorporating CD4+ T 
cell number in memi mice which indicates that memi's lymphocytes are hyper-proliferative. 
 
In a normal lymphocytic peripheral environment, mature T cells remain quiescent and 
immunologically naive until they are activated by APC (Boyman et al., 2009). These naïve 
quiescent cells are characterised by a low expression of CD44 and a high expression of 
CD62L (Murali-Krishna and Ahmed, 2000). In contrast, we have observed that the majority 
of dCKmem/mem T lymphocytes in the periphery actively proliferate (fig. 41 and 42) and 
express an effector memory phenotype (CD44hiCD62Llo) (fig. 43). This implies that memi's 
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lymphocytes are under extensive homoestatic proliferation. In addition when naïve 
quiescent CD44loCD62Lhi wild type donor cells are transferred to memi recipient, they 
proliferate (fig. 55) and acquire an effector memory phonotype (fig. 54). This also supports a 
model of LIP in dCKmem/mem mice. At the same time, however, we found that memi 
lymphocytes are able to proliferate by cell-intrinsic mechanism. They remained highly 
proliferative even 35 days after adoptive transfer in a wild type environment (fig. 55). 
Considering all these results, we suggest that proliferation in memi mice is driven by both 
cell-intrinsic and -extrinsic mechanisms. Here are our hypotheses and possible experiments 
to confirm them; 
 
1/ Cell-intrinsic proliferation: A decrease in DCK functionality could interfere with 
intracellular regulators of cell proliferation. To support this hypothesis, we observed that 
the expression of p27Kip1 and its transcriptional activator Foxo3a is downregulated in 
dCKmem/mem splenocytes (fig. 46). It has been reported that a constitutive suppression of 
Foxo3a induces cell cycle progression (Brandts et al., 2005). In addition, we found that 
STAT5 is downregulated and that the active phosphorylated form of p38 is upregulated 
while PTEN or PDK1 expression was wild type (fig. 47 and 48). Even though the Akt data is 
missing due to technical problems, these preliminary data suggest that DCK deficiency might 
affect molecules in the JAK/STAT/MEK/p38 signalling pathways. To test this hypothesis, we 
can investigate the expression of upstream molecules in the p38-Foxo3a signalling pathway. 
Since p38 is regulated by MKK3 and MKK6 (Davis, 2000), we can first test their expression 
and if they are also affected, then we “climb up” the signal pathway. In addition, we will 
treat wild type cells with p38 inhibitor (or inhibitors of other signalling molecules in these 
pathways) in vitro and see how these treatments affect the stimulus-independent 
proliferation and proliferation-induced apoptosis.  
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Figure 60: Signal pathways controlling cell cycle and proliferation  
Cell proliferation is regulated by various signalling molecules. The activation of Foxo3a, one 
of the key proliferation inhibitor, is controlled by number of molecules for example, ERK, 
p38 and Akt. ERK and p38 are controlled by MKK/MEK/MAPK signalling pathways which 
are activated by various external stimuli. Another Foxo3a inhibitor Akt is activated by 
PI3K/PDK1 pathway.  
 
In addition, we also have to investigate further whether the reduced Foxo3a expression in 
dCKmem/mem splenocytes is due to a real change in activation or to the change in splenic cell 
population. As the western blot analysis was performed on whole dCKmem/mem splenocytes 
which contain significantly higher number of cells from myeloid origin and since dCK is also 
expressed in myeloid cells (Mansson et al., 1999), it would be interesting to repaet the 
analysis on bead-purified splenic lymphocytes. 
 
2/ Cell-extrinsic proliferation: We hypothesise that it is the lymphopenic peripheral 
environment in memi mice that drives the cell-extrinsic lymphocyte proliferation of both 
memi cells and wild type transferred cells. This lymphopenic environment would increase 
the relative amount of γ-cytokines (IL-7,IL-2 and IL-15) available for each peripheral cell, 
therefore, lymphocytes are highly proliferative. This hypothesis could be tested by 
correcting memi's lymphopenic environment. We could inject large numbers of wild type 
115 
 
lymphocytes into dCKmem/mem recipients and analyse the proliferation of endogenous or 
additional wild type injected cells. To test the effect of γ-cytokines on proliferation, we 
could block γ-cytokines by either injecting specific inhibitors or using RNAi to prevent their 
production, and observe memi cells proliferation pattern. Another way to test this is to cross 
memi mice with IL-2 and IL-15 double knock-out mice and check if their cells are still 
proliferating.  
 
Similarly, when dCKmem/mem mice are infected with LCMV, their oligoclonal CTL population 
undergoes an abnormal hyper-proliferation and becomes highly senescent (KLRG-1hiIL-7Rαlo) 
(fig. 21). This could result from both a distorted proliferation control mechanism and from 
the effect of the DCK-deficient environment. To test the cell-intrinsic effect of the mutation 
during the LCMV immune response, we first find out how DCK interacts with the 
proliferation signalling molecules and artificially correct the affected signalling pathway by 
for example, using inhibitors. Subsequently, we infect mice and see if they still present an 
abnormal hyper-proliferation. To investigate a potential cell-extrinsic control of LCMV 
immune response, we could adoptively transfer memi cells to non-irradiated wild type 
recipients and infect them with LCMV. If the behaviour of memi donor cells is similar to that 
of Ag-CTL wild type cells, we might be able to conclude that memi's abnormal immune 
phenotype is also driven by an effect of the DCK-deficient environment.   
 
In dCKmem/mem mice, we also observed a significant increase in cells of myeloid origin (fig. 40). 
To understand their behaviour, the following experiments could be performed: 
 
1/ Measurement of proliferation and apoptosis in myeloid cells: Since dCKmem/mem 
lymphocytes already present hyper-proliferation and apoptosis, we might expect similar 
observations in myeloid cells. Since the numbers of myeloid cells were far greater than that 
of lymphocytes, they might have stronger proliferation potential than lymphocytes or might 
be more resistant to apoptosis.  
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2/ Analysis of myeloid cell development: The fact that memi mice have a significant increase 
in myeloid cell numbers could imply that DCK-deficiency could increase the proportion of 
myeloid lineage progenitors (Flk-2+Lin-c-kit+Sca-1-CD16/32int) in the bone marrow. This could 
be easily measured by flow cytometry.  
 
3/ Mechanism of proliferation and apoptosis: By adoptively transferring memi's myeloid 
cells, for example DC purified by microbeads to wild type recipients, we might be able to 
address whether the proliferation and apoptosis are driven by cell-intrinsic or cell-extrinsic 
factors.  
 
4/ Analysis of erythropoiesis: Ter-119 is a marker which delineates erythroid linage cells. In 
memi mice, there is a significant increase of Ter-119+ cell in the periphery (fig. 40) and 
splenomegaly which might imply their abnormal extramedullary haematopoiesis at their 
prenatal stage. This could be further investigated by starting histological studies with memi's 
splenic tissue samples. By comparing memi's tissue samples with that of wild type mice 
(Suttie, 2006), their extramedullary haematopoiesis could be examined. If there is a defect, 
it could be studied further in relation to erythropoietin response via JAK/STAT signal 
pathways to regulate erythropoiesis (Lopez et al., 2011). In addition, it is also possible to 
suspect that memi mice would suffer from polycythemia due to increased erythroid cells. To 
test this, we could measure the haemoglobulin concentration in memi's blood as appeared 
in Rosenblit et al., 1999 (Rosenblit et al., 1999).  
 
5. Apoptosis in the periphery 
In addition to the hyper-proliferation, the second notable phenomenon in dCKmem/mem mice 
is an increased apoptosis of peripheral lymphocytes (fig. 49-51). From the results of the 
adoptive transfer experiment (fig. 56), we hypothesise that memi's increased level of 
apoptosis is also controlled by both cell-intrinsic and -extrinsic mechanism. Our hypotheses 
and suggested experiments are: 
 
1/ Cell-intrinsic apoptosis: When the level of Foxo3a is reduced, cells will undergo 
uncontrolled proliferation due to disrupted cell cycle check-point control (Potente et al., 
117 
 
2003). Consequently, tumour-suppressor genes such as p53 and pRb would be expressed 
and activate apoptosis. Therefore, interference of DCK with signalling pathways that control 
Foxo3a activation could induce apoptosis. After establishing which signalling molecule is 
influenced by the lack of DCK, we can test this Foxo3a deficiency-induced cell death model 
by rectifying the affected pathway to restore Foxo3a expression and measuring the 
activation levels of Foxo3a and tumour-suppressor genes.  
 
2/ Cell-extrinsic apoptosis: A severe dNTP imbalance caused by 5-Fluorodeoxyuridine 
treatment induces DNA double strand damage and subsequent cell death in mouse tumour 
cells (Yoshioka et al., 1987). Even a moderate perturbation of dNTP pools is enough to affect 
the fidelity of DNA replication, increase mutations frequency and induce cell death 
(Martomo and Mathews, 2002). In addition, dNTP pool imbalance caused by ADA-deficiency 
can induce apoptosis (Apasov et al., 2001). Finally, when the dNTP pool is affected by a 
reduced activity of ribonucleotide reductase (RNR) and thymidine kinase (TK) due to IL-3 
deprivation, hematopoietic cells undergo apoptosis caused by increased DNA fragmentation 
(Oliver et al., 1996). We can therefore hypothesise that the absence of functional DCK would 
perturb the dNTP pool and induce the apoptosis of memi lymphocytes. This hypothesis can 
be tested by correcting dNTP pool imbalance artificially and monitoring the apoptotic rate of 
memi lymphocytes. 
 
Finally, we suspect that the increased apoptosis observed in memi cells and wild type donor 
cells transferred into memi recipients is a side-effect of LIP. It has indeed been reported that 
cells proliferating in a lymphopenic environment are more susceptible to Bim- and Fas-
mediated apoptotic cell death (Fortner and Budd, 2005). To confirm this hypothesis, we can 
measure the expression levels of Bim and Fas in memi cells and wild type donor cells 
transferred to memi recipients.  
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Conclusion 
 
Our memi mutant was generated during our ENU mutagenesis and isolated by testing its 
immune response to LCMV Armstrong infection. A single transversion (G → T) at 739bp in 
exon 6 of dCK gene causes the loos of the last 14 amino acids of DCK. This results in a null 
mutation. We have shown that this truncated DCK disrupts normal lymphocyte 
development and peripheral lymphocyte proliferation and apoptosis in both cell-intrinsic 
and -extrinsic manners. Our dCK complete loss-of-function mutant will be useful to study 
the significance of the last 14 amino acids for DCK activity and to investigate DCK interaction 
with other signalling molecules which induce cell proliferation and apoptosis.   
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PART 3: binu 
 
Background  
 
1. Memory cell populations 
After viral clearance, CD8+ T cells which have the potential to become memory cells will re-
express high levels of the IL-7 receptor (IL-7Rα) and low levels of the T-box transcription 
factor (T-bet) (Joshi et al., 2007). These cells share two major common phenotypes: an 
enhanced ability to self-renew and the ability to rapidly express effector genes and 
proliferate upon re-infection by the same pathogen. However, the population of CD8+ 
memory T cells is not homogeneous. Based on the expression of the lymph node homing 
receptor CD62L and the chemokine receptor CCR7, the memory CD8+ T cells can be 
subdivided into central (Tcm; CD62L+CCR7+) and effector (Tem; CD62L-CCR7-) memory cells 
which respond differently to secondary viral infection (Sallusto et al., 1999). Since Tcm 
expresses high levels of CD62L and CCR7, they usually circulate in secondary lymphoid 
organs while Tem resides in non-lymphoid zones of the spleen or other peripheral tissues to 
provide an immediate reaction to infections (Masopust et al., 2001; Weninger et al., 2001). 
Upon infection, Tem cells immediately present effector-like functions such as cytotoxic 
killing activities (expression of perforin) and produce IFNγ to defend the host (Sallusto et al., 
1999). On the other hand, Tcm can produce more IL-2 to support T cell proliferation. In 
addition, adoptively transferred Tcm generated new Tem cells upon challenge (Unsoeld and 
Pircher, 2005).  
 
The equilibrium between the Tcm and Tem populations is regulated by several genes. For 
example, when the transcription factor Klf2 is activated by the PI3K/mTor pathway, the 
expression of CD62L and CCR7 is downregulated, affecting the proportion of Tem and Tcm 
cells (Sinclair et al., 2008). In addition, the Inhibitor of DNA binding 2 (Id2) (Cannarile et al., 
2006) and Blmip-1 (Rutishauser et al., 2009) favour a Tem development, while Bcl-6 
facilitates Tcm formation (Ichii et al., 2004).  
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2. LCMV epitope  
LCMV's viral genome contains a 7.2 kb large (L) and a 3.4 kb small (S) segments. The S 
segment encodes 3 structural protein, the nucleocapsid protein (NP) and 2 surface 
glycoproteins, GP1 and GP2 (Oldstone et al., 1995). Only viral peptides produced from the S 
segment are recognised by the TCR to generate CTL (Riviere et al., 1986). When mice of the 
H-2b haplotype, for example C57BL/6J mice, are infected with LCMV, the expansion of CTL is 
largely directed against np396-404 (FQPQNGQFI), gp33-41 (KAVYNFATC) and gp276-286 
(SGVENPGGYCL) presented by Db MHC class I molecules (Gairin et al., 1995). During acute 
infections, CTL expansion relies on one or two epitopes, such as np396 and gp33, but it has 
been reported that upon prolonged viral infection, CTL can also expand in response to 
subdominant epitopes such as gp92-101 and np205-212 (van der Most et al., 1998).  
 
Results 
 
1. Isolation of the binu mutation 
Our second mutant was isolated after screening 130 more G3 mice after the identification of 
memi. The mutation is transmissible in the germline (2 mutants /6 littermates in the retest 
data), uninfected mutants breed normally and do not show any health problems. The 
original mutant mouse was isolated based on a significant reduction of KLRG-1hi senescent 
effector cells and a higher level of IL-7Rα+ memory precursors at the peak of CTL expansion 
and at the end of contraction (fig. 61). Because of this expansion of IL-7Rα+ memory 
precursor cells at day 21, the mutant was named binu, which means soap in Korean, as 
memory precursor population expanded like soap bubbles. Their percentage of gp33-
specific CTL in the blood remained similar to that of wild type littermates (fig. 62).  
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Figure 61: binu mutants showed a distinctive immune response upon LCMV Armstrong 
infection 
Six-week old binu mice were injected with LCMV Armstrong and their populations of 
effector (KLRG1+IL-7R-gp33+CD8+; upper left for %cells, lower left for absolute cell 
number) and of memory precursors (KLRG1-IL-7R+gp33+CD8+; upper right for %cells, 
lower right for absolute cell number). Ag-CTL was measured at 8 and 21 days after the 
infection. The experiment shown is representative of at least 12 independent experiments. 
Here, n = 8 for wt and 6 for binu. In all experiments, statistical analysis was performed as 
described in the material and methods. Wild type littermates are represented as closed circles 
(●), and binu mice are represented as open triangles (∆). Error bars represent standard 
deviation unless otherwise stated and *p<0.05, **p<0.01, ***p<0.001. 
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Figure 62: The binu mutation does not affect the percentage of gp33+CD8+ cells upon 
LCMV Armstrong infection 
Six-week old mice were injected with LCMV and their populations of gp33-specific CD8+ T 
cells were measured at day 8 and day 21 after the infection. The experiment shown is the 
combination of 3 experiments. n = 57 for wt and 12 for binu.  
 
2. binu mutants present wild type peripheral blood composition 
When we investigated naive binu's peripheral blood composition by staining PBL with 
various markers (fig. 63), we found that their lymphocyte and NK/NKT cell composition was 
normal. We then had a closer look at their CD8+ T lymphocytes for their apoptosis and 
activation status. The expression levels of apoptotic markers (Annexin V, FasL) in CD8+ T cells 
were similar to wild type mice and they did not seem to be activated as indicated by a wild 
type CD122, CD44 and CD62L expression. From these results, binu mutation might not be 
involved in lymphocyte development but rather only involved in the memory immune 
response to viral infections.  
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Figure 63: Naive binu mice present normal peripheral blood composition, activation 
and apoptosis  
Blood samples from six-week old mice were collected and tested for their blood cell 
composition (top graph; CD8+ and CD4+ T-cells NK1.1+CD3- NK cells and NK1.1+CD3+ 
NKT-cells), cell death (bottom left graph; Annexin-V+, FasL+), and homeostatic activation 
markers (bottom right graph; CD122+, CD44+ and CD62L+). The experiment was done once, 
n = 13 for wild type littermates and 9 for binu.  
 
3. binu is a recessive mutation and establishment of a stable mutant strain 
We believe that the binu mutation behaves in a recessive manner as the homozygous and 
heterozygous ratios obtained with different combinations of parents follows the Mendelien 
laws of inheritance for recessive mutations (table 12). 
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 # binu 
mutants 
# total offspring 
tested 
Mutant 
ratio 
Expected Mendelian ratio 
for a recessive mutation 
Het x WT 0 12 0 0 
Het x Het 14 48 29% 25% 
Hom x Het 3 6 50% 50% 
Hom x Hom 8 8 100% 100% 
Table 12: binu behaves as a recessive mutation 
Mutant ratios obtained by testing offspring from parents of different combinations of 
genotypes are comparable to the expected Mendelian ratios for a recessive mutation. Het x 
WT refers to G1 x WT, Het x Het refers G1 x G2 (the original parents), Hom x Het and Hom 
x Hom pairs were defined by the mutant ratio of their offspring.  
 
The absence of phenotype in naïve mice implicated that the breeding of the binu mutation 
to homozygosity had to be done based on the LCMV infection phenotype. Unfortunately, 
LCMV infected mice could not be used for breeding because LCMV Armstong is a Level 3 
pathogen. As a consequence, once mice had been infected, we could not bring them out of 
the containment room to a pathogen-free breeding room. Therefore, to breed the mutation 
to homozygosity, we relied on Mendelian mode of genetic inheritance as explained in the 
introduction of this thesis. We knew that if the original G1 x G2 parents were heterozygous 
to the mutation, 25% of the G3 offsprings should be homozygous for the mutation. Using 
this information, we started setting up breeding cages using pups from the original G1xG2 
parents (fig. 64). Followed by subsequent breeding and testing, we have recently obtained a 
homozygous breeding pair that we are amplifying for genotyping and further phenotyping.   
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Figure 64: Breeding scheme used to obtain a binu homozygous stock 
This diagram depicts the breeding scheme used to establish a homozygous binu strain. 
Random pairing was performed until we reaching a 100% mutant ratio for one of the 
breeding cages.  
 
4. Increased long-term CD8+ T memory population in binu mutants  
To see if the increase in memory precursors at day 21 translated into a long-term increase in 
Ag-memory cells, we kept LCMV infected binu mice for up to 70 days and analysed the 
quantity and quality of their memory cells using gp33 tetramer, CD8, KLRG-1 and IL-7Rα. As 
a result, we observed a higher percentage of gp33+CD8+ T cells in binu's splenocytes over 
the duration of the experiment (fig. 65). In addition, we confirmed that binu mice retained a 
relatively lower percentage of KLRG-1 expressing and a relatively higher percentage of IL-
7Rα expressing cells compared to their wild type littermates (fig. 66). These data indicate 
that the binu mutation enhances CD8+ T cell memory formation and long-term maintenance 
upon LCMV infection.    
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Figure 65: Time course of gp33+CD8+ cells in the spleen of binu mice upon LCMV 
infection 
After 9, 22, 50 and 70 days of LCMV Armstrong infection, splenocytes were harvested and 
stained with gp33 tetramers. Black continuous line represents wt littermates and grey dashed 
lien represents binu mice. At least n = 3 for both wt littermates and binu mice were tested per 
time point.  
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Figure 66: Time course of KLRG-1+ (left) and IL-7Rα+ (right) cells in gp33+CD8+ 
splenocytes upon LCMV infection 
After 9, 22, and 70 days of LCMV Armstrong infection, splenocytes were harvested and 
stained with KLRG-1 and IL-7Rα to distinguish KLRG-1+IL7Rα- (left) and KLRG-1-IL-7Rα+ 
(right) population in gp33+CD8+ cells. Black continuous line represents wt littermates and 
grey dashed lien represents binu mice. At least n = 3 for both wt littermates and binu mice 
were tested per time point.  
 
5. Change in percentages of LCMV epitope specific cells 
We next decided to investigate the behaviour of a different epitope-specific cells, np396-
specific cells, in binu mice. To our surprise, we observed a significant reduction in np396-
specific CTL in the peripheral blood at day 8 and day 21 after LCMV infection (fig. 67). We 
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also analysed the quality of these CTL using KLRG-1 and IL-7Rα (fig. 66), but the pattern we 
detected was not very different from what we obtained with gp33-specific CD8+ T cells (fig. 
70). From these data, we suspect that in addition to its positive effect on memory 
development and maintenance, the binu mutation might alter CTL TCR repertoire and/or 
TCR antigen recognition ability. 
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Figure 67: The binu mutation causes a reduction in np396+CD8+ specific cells upon 
LCMV Armstrong infection 
Six-week old mice were injected with LCMV and their populations of np396-specific CD8+ 
T cells measured at day 8 and day 21 after infection with LCMV. The experiment shown is 
representative of 3 experiments. Here, n = 31 for wt and 6 for binu.  
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Figure 68: binu mutants show a distinctive immune response upon LCMV Armstrong 
infection 
Six-week old binu mice were injected with LCMV Armstrong and their populations of 
effector (KLRG1+IL-7R-np396+CD8+, left) and of memory precursors (KLRG1-IL-
7R+np396+CD8+, right) antigen-specific T-cells measured in the peripheral blood at 8 and 21 
days after infection. The experiment shown is representative of 2 independent experiments. 
Here, n = 9 for wt and 3 for binu.  
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6. binu favours Tem development  
We next analysed the profile of CD8+ memory pool after LCMV infection by using CD62L and 
CCR7 to distinguish effector memory (Tem; CD62L-CCR7-) and central memory (Tcm; 
CD62L+CCR7+) cells (Unsoeld et al., 2004). At 70 days post-infection, binu mice presented a 
higher population of splenic Tem as compared to wild type littermates and less splenic Tcm 
were detected (fig. 69). These data indicate that the binu mutation enhances the 
development of Tem and/or impairs Tcm differentiation among memory population. 
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Figure 69: binu mice have more Tem than Tcm in their memory compartment upon 
LCMV infection  
After 9, 22, 50 and 70 days of LCMV Armstrong infection, splenocytes were harvested and 
stained with CD62L and CCR7 to distinguish Tem (left) and Tcm (right) population in 
CD44+CD8+ T cells. Black continuous line represents wt littermates and grey dashed lien 
represents binu mice. This experiment was done once with at least n = 3 for both wt 
littermates and binu mice at each time point.  
 
Discussion  
 
Currently, we are mapping the binu mutation. In the meantime, the comparison of binu's 
phenotypes with other known mutant mice can provide us with a list of possible candidate 
genes. Some of them are currently being sequenced in order to speed up the cloning of the 
mutation and the phenotypic investigation. Some possible candidate genes and descriptions 
of knock-out models are listed below (table 13), but interestingly, we have not found a 
knock-out strain with exactly the same phenotype as binu yet. This gives us hope that the 
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binu gene might be a novel gene which controls CD8+ T memory cell formation, or might be 
a new function for a known immune regulator.  
 
GENE FUNCTION PHENOTYPE REFERENCE 
BIM proapoptotic Bcl-2 family 
Bim-/- mice after LCMV infection:  
↑%IL-7Rα- cells during contraction phase (more survival of 
effector cells) 
↑%IL-7Rα+ cells in memory phase due to re-expression of IL-
7Rα in IL7Rαlo cells 
↑%gp33+CD8+ and %np396+CD8+ T cells 
binu mice after LCMV infection : ↑%IL-7Rα, %gp33+CD8+ at 
day 21, but ↓%np396+CD8+ T cells 
(Wojciecho
wski et al., 
2006a) 
T-bet Transcription factor 
↓T-bet expression in IL-7Rαhi cells upon LCMV infection  
t-bet KO mice after LCM infection: 
↓%LCMV-specific CD8 cell from day 8 
↑ %IL-7RαhiCD44+ (gp33+CD8+) at day 8 post-infection 
↑%CCR7+, IL-7Rα+, CD62L+ (more Tcm) and ↓%KLRG-1+ in 
LCMV-specific CD8 cells 
binu mice after LCMV infection: ↑%gp33+CD8+ splenocytes 
day 21 after infection, ↓%Tcm and ↑%Tem 
(Intlekofer 
et al., 2007) 
  t-bet KO: ↓%IFNγ producing cells in response to T. gondii (Mayer et al., 2008) 
GABPα 
 
transcription factor 
(NRF-2, E4TF1-60) 
GABPα (GA binding protein α) is required to maintain higher 
expression of IL-7Rα in memory precursor CD8 T cells upon 
LCMV infection  
binu: ↑% IL-7Rαhi cells upon LCMV infection 
(Chandele 
et al., 2008) 
GFI1 transcription factor 
GFI1 (growth factor independence 1) is required to repress 
IL-7Rα transcription in CD8 effector T cells upon LCMV 
infectiond  
(Chandele 
et al., 2008) 
  
gfi-1 KO: neutropenia, early lethality, ↓thymic cellularity 
but normal peripheral CD8 and CD4 T cells 
binu: no observed lethality and normal thymic cellularity 
(Hock et al., 
2003) 
Blimp-1 
transcriptional 
repressor of B cell 
terminal 
differentiation 
prdm1 KO mice after LCMV infection: 
↑% IL-7Rαhi CD62L+, ↓%KLRG-1+ at d8 and d60 
↑%IL-2, IFNγ producing cells but delayed viral clearance 
↑%LCMV-CTL after d8 
binu after LCMV infection: %IL-7Rαhi, Ag-CTL, KLRG-1+ CD8 T 
cells are similar to pdrm1 KO in PBL, but no significant 
increase in CD62L expression 
(Rutishauser 
et al., 2009) 
MyD88 
adaptor protein 
required for TLR 
signal transduction 
myD88 KO mice after LCMV infection: 
↓%Ag-CTL, impaired viral clearance 
binu after LCMV infection: %gp33+CD8+ T cells is wild type  
(Rahman et 
al., 2008) 
IL-2 inflammatory cytokine 
IL-2 upregulates expression of Eomes, Perforin, and IFNγ but 
downregulates expressionn of Bcl-6, IL-7Rα via STAT5 
il2 KO CD8 T cells after LCMV infection: 
↑Bcl-6 expression, ↓Perforin, GrB, KLRG1, T-bet expression 
on CTL, poor CTL killing ability 
binu after LCMV infection: ↓%KLRG-1+ CD8 T cells, but no 
autoimmunity observed 
(Pipkin et 
al., 2010) 
Table 13: A candidate genes list for binu mutation  
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1. Candidate genes for binu mutation 
Among the listed genes, some potential candidate genes are discussed below:  
 
1.1 B lymphocyte-induced maturation protein -1 (Blimp-1) 
Blimp-1 (encoded by Prdm1) was originally described as a transcriptional repressor which is 
essential for the development of plasma B cells (Martins and Calame, 2008; Shapiro-Shelef 
et al., 2003). Mice lacking Prdm1 in the germline suffer from a lethal inflammatory disease 
due to the excessive accumulation of CD44hiCD62Llo CD4+ and CD8+ T cells (Kallies et al., 
2006). As a consequence, the in vivo study of Blimp-1 deficiency is only possible in 
conditional knock-out models. When mice deficient for Blimp-1 in CD8+ T cells are infected 
with LCMV Armstrong, they develop a smaller pool of effector senescent cells (KLRG-1hiIL-
7Rαlo) and a larger population of memory precursors (KLRG-1-IL-7Rα+) with increased CD62Lhi 
Tcm population (Rutishauser et al., 2009). An increase in Tcm cells was not observed in binu 
mutants which present a significant increase in Tem (CD62L+CCR7-) population (fig. 69). 
Because binu mice had a decrease in CD62L expression, which is an opposite phenotype to 
the Prdm1 knock-out mice, the binu mutation could be a gain-of-function mutation of Blimp-
1. However, it is difficult to imagine binu as a gain-of-function mutation in Prdm1 as binu 
mutants also showed a reduction of KLRG-1+IL-7Rα- cells and a greater expansion of KLRG-
1loIL-7Rαhi CD8 T cells upon LCMV infection.  
 
1.2 T-box family of transcription factors T-bet 
T-bet, encoded by Tbx21, is a member of the T-box family of transcription factors and is 
known to control the formation of KLRG-1+IL-7Rα- CTL at the expense of CD62LhiCCR7lo Tcm 
cells upon LCMV infection (Intlekofer et al., 2007; Joshi et al., 2007). Naïve Tbx21-/- mice also 
present a lack of NK cells (Intlekofer et al., 2005).  
Like the T-bet null mutant, binu mice present a reduction in KLRG-1+IL-7Rα- CTL population 
and an increased Tem memory cell population (fig. 69). However, we could not find any 
notable decrease in NK cell population in binu's peripheral blood (fig. 63) which could 
indicate that binu does not affect T-bet.  
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1.3 Bcl-2 interacting mediator of death (Bim) 
Bim-/- mice present an altered haematopoiesis with perturbation in T cell development and 
older mice suffered from autoimmune kidney diseases (Bouillet et al., 1999). However, the 
analysis of Bim-/- mice upon LCMV infection has revealed that this pro-apoptotic Bcl-2 family 
member is responsible for the contraction of IL-7α- CTL (Wojciechowski et al., 2006b). As a 
result, mice lacking Bim can maintain significantly high levels of gp33+ and np396+ specific T 
cells which are resistant to apoptosis during the contraction phase. In addition, these CTLs 
are highly functional upon LCMV peptide stimulation as they produce more IFNγ and IL-2 
than wild type control cells. 
binu mice do not present any T cell developmental problems or sign of illness, at least up to 
14 months of age. Upon LCMV infection, binu affects the gp33 and np396 specific cells in a 
different manner (fig. 62 and 67), which is not what is observed in Bim-/- mice. However, as 
we observed similar phenotypes such as an increase in IL-7α+ CD8+ T cells and gp33+CD8+ T 
cells at the end of contraction phase, we suspected that binu could be a Bim loss-of-function 
mutation. However, we recently sequenced Bim’s exons in a binu mutant mouse and found 
no mutation, indicating that binu most probably does not affect Bim. 
 
2. Epitope-specific expansion of binu's CTL 
Among LCMV H-2b peptides, np396-404 binds to MHC class I Db with higher affinity than 
gp33-41 (van der Most et al., 1998). Therefore, when C56BL/6J mice are infected by LCMV, it 
is normally expected that they will have more np396-specific CTL than gp33-specific CTL. 
However, binu mice presented significantly less np396-specific CTL than wild type mice (fig. 
67) while their gp33-specific CTL expansion is not affected (fig. 62).  
There are few factors which could affect immunodominance during an immune response: 
intracellular antigen processing, antigen binding affinity to MHC molecules, and finally, TCR 
repertoire (van der Most et al., 1998). Several hypotheses could explain a potential altered 
antigen processing and epitope recognition mechanisms in binu mice;  
 
1/ Intracellular antigen processing: In binu mice, we observed wild type levels of gp33-
specific CTL population which implicates that their intracellular antigen processing 
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machinery might work normally. If this machinery was affected by binu mutation, the mice 
would have a decrease in all LCMV epitope-specific CTL population. Therefore, we could 
carefully rule out this hypothesis as an explanation to the defective np396-specific CTL 
population.  
 
2/ Peptide binding affinity to MHC molecule: Peptide-MHC binding affinity is mainly 
determined by the peptide amino acid motif and the MHC pocket structure. However, in vivo, 
environmental factors such as cytokine availability can also affect this affinity. As an example, 
according to in vitro assay, gp276 has 10-fold higher affinity to MHC class I Db molecule than 
gp33, but in vivo, the anti-gp33 response dominates the gp276 one (van der Most et al., 
1998). This is thought to be due to presence of IFNγ which is produced by Th1 and NK cells 
upon infection (Basler et al., 2004).  
Similarly, we could suspect that the binding affinity of np396 might be affected by binu's 
environmental factors. This could be investigated by measuring the antiviral and pro-
inflammatory cytokines production in binu mice upon infection. 
 
3/ TCR repertoire: During T cell development, the TCR-β chain undergoes V(D)J 
recombination. If the binu mutation affects V(D)J rearrangement and selectively inhibits a 
particular combination which is crucial to recognise np396, CTL eventually will not be able to 
respond normally to np396 presentation. The diversity of TCR in LCMV epitope recognition 
could be tested by a TCR/CDR3 spectratyping (Memon et al., 2011) on purified CD8 T cells.  
 
Finally, we can measure other epitope-specific CD8+ T cell numbers in binu mice to 
investigate whether other epitope presentation and recognition are affected. 
 
3. Increased memory formation and the limited "space" in the immune system 
At day 70 post-LCMV infection, we found that binu mice retain twice more LCMV-specific 
CD8+ T cells than wild type mice (fig. 65). If this increase in memory cells is confirmed to be 
functional, binu mutants might have an advantage upon a secondary infection with LCMV 
compared to wild type mice. However, if binu mice produce more memory cells upon every 
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infection with different pathogens, their memory pool space might be "filled up" to quickly. 
To test how binu mice manage their memory pool size, we could infect binu mice with 
different types of virus and measure the various populations of memory cell and their 
dynamics. This will allow us to investigate how memory pool size is controlled to avoid or 
tolerate abnormal memory cell expansion.  
 
Conclusion 
 
Our second mutant, binu, is characterised by an increased memory CD8+ T cell population, 
especially Tem upon LCMV Armstrong infection. From the staining of PBL of uninfected 
animals, we found that the binu mutation does not disrupt the peripheral blood composition 
and their lymphocytes do not undergo abnormal apoptosis. To our knowledge, there is no 
reported mutation which presents the exact same phenotype as binu. Because of its unique 
characteristics, this mutant will be a good model to understand the mechanism of CD8 
memory formation.  
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PART 4: alois 
 
Results 
 
1. Isolation of the alois mutation 
The screen of a total of 1149 G3 mice (292 mice after the isolation of binu) allowed us to 
isolate our third germline mutation. This mutant presents an increased level of effector cells 
and a reduced ratio of memory precursor at the peak of the expansion and at the end of the 
contraction (fig. 70). Their level of gp33-specific CD8+ T lymphocytes is not affected (fig. 71). 
Because they lack memory precursors, we called them alois, in reference to Alois Alzheimer, 
who first described the symptoms of the Alzheimer disease. alois mice are healthy and 
breed normally until 13 months of age.  
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Figure 70: alois mutants showed distinctive immune responses upon LCMV Armstrong 
infection 
Six-week old mice were injected with LCMV Armstrong and their populations of effector 
(KLRG1+IL-7R-gp33+CD8+, left graph) and of memory precursors (KLRG1-IL-
7R+gp33+CD8+, right graph) antigen-specific T-cells in peripheral blood measured at 8 and 
21 days after infection. The experiment shown is representative of at least 12 independent 
experiments. Here, n = 5 for wt and at least 4 for alois. In all experiments, statistical analysis 
was performed as described in the material and methods. Wild type littermates are 
represented as closed circles (●), and alois mice are represented as open squares (□). Error 
bars represent standard deviation unless otherwise stated and *p<0.05, **p<0.01, ***p<0.001. 
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Figure 71: The alois mutation does not affect the gp33+CD8+ cell population upon 
LCMV Armstrong infection 
Six-week old G3 mice were injected with LCMV and their populations of antigen-specific 
CD8+ T cells (gp33+CD8+) measured at day 8 and day 21 after infection. The experiment 
shown is representative of at least 12 experiments. n = 5 for wt and at least 4 for alois. 
 
2. alois does not affect PBL lymphocyte composition or cell behaviour 
To check whether alois mice suffer from any developmental defect or peripheral 
lymphocyte behaviour problem, we stained their PBL for lymphocytes populations (CD8, 
CD4, and B220), their rate of apoptosis (Annexin V) and of homeostatic proliferation (CD122, 
CD44 and IL-7Rα) (fig. 72). The blood profile of alois mice looks very similar to that of their 
wild type littermates.  
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Figure 72: The alois mutation does not cause any change in peripheral blood 
lymphocyte composition, apoptosis and proliferation  
Blood from six-week old wild type and alois mice was tested for their lymphocyte 
populations (top left graph; CD4+, CD8+, B220+), lymphocyte level of cell death (top right 
graph; Annexin-V+), and homeostatic activation (CD122+, CD44+, IL-7R+) in CD8+ T 
(bottom left graph) and CD4+ T lymphocytes (bottom right graph). This experiment was done 
once with n = 9 for wild type mice and 8 for alois mice.  
 
3. The alois mutation behaves as a recessive trait 
We believe that the alois mutation behaves as a recessive trait for the following reasons: 
A heterozygous x pure wild type C57BL/6J breeding pair did not give any alois phenotype. 
This would therefore indicate that the mutation is recessive. However, from a heterozygous 
x heterozygous breeding pair, we obtained a mutant ratio of 45%, which is higher than the 
expected Mendelian ratio of 25% expected for a recessive mutation. This could indicate that 
the mutation is a dominant trait with a weak penetrance. However, we still believe alois 
behaves as a recessive mutation because:  
 
1/ We only tested 11 littermates from our Het x Het pair and can expect ratios to vary a lot if 
we increase the size of the tested group.  
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2/ If the mutation was dominant with a weak penetrance, some of their offspring would 
never present a mutant phenotype and we would therefore never be able to have a 100% 
mutant ratio from any breeding pairs. This is not the case for the alois mutation as we 
obtained 100% mutant ratio.  
 
To confirm by which manner the alois mutation is inherited, we have to test more pups 
from Het x Het but more reliably from a confirmed Hom x WT breeding pair.  
 
 # alois 
mutants 
# total offspring 
tested 
Mutant 
ratio 
Expected Mendelian ratio 
for a recessive mutation 
Het x WT 0 10 0 0 
Het x Het 5 11 45% 25% 
Hom x Hom 9 9 100% 100% 
Table 14: alois behaves as a recessive mutation 
Mutant ratios obtained by testing offspring from parents of different combinations of 
genotypes are compared to expected Mendelian ratio for a recessive mutation. Het x WT 
refers to G1 x WT, Het x Het refers to G1 x G2 (the original parents) and Hom x Hom pairs 
were defined by the mutant ratio in the offspring.  
 
Naive alois mice did not present any detectable phenotype that could be used to establish a 
stable homozygous stock. We therefore relied on the same strategy as we did for binu to 
breed the mutation to homozygosity (table 14). This allowed us to recently establish a 
homozygous breeding pair.  
 
We are currently outcrossing alois males to 129SvlmJ females to obtain hybrid mice to be 
used for mapping. At the same time, we will sequence some candidate genes based on 
reported phenotypes of existing mutant strains.  
 
Discussion  
 
Upon LCMV infection, alois mutants present high levels of senescent CTL and reduced levels 
of quiescent memory cells. To our knowledge, they do not present any problems in their 
peripheral blood lymphocyte composition (fig. 72). Like for binu, the alois mutation is 
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currently being mapped. Some possible candidate genes are however already being 
investigated. They are discussed below.  
 
GENE FUNCTION PHENOTYPE REFERENCE 
T-bet Transcription factor 
↓T-bet expression in IL-7Rαhi cells upon LCMV infection  
t-bet KO mice after LCM infection: 
↓%LCMV-specific CD8 cells 
↑ %IL-7RαhiCD44+ (gp33+CD8+) at day 8 post-infection 
↑%CCR7+, IL-7Rα+, CD62L+ (more Tcm) and ↓%KLRG-1+  
alois mice after LCMV infection: ↓%IL-7Rα, no information 
about %Tcm and Tem 
(Intlekofer 
et al., 2007) 
GABPα 
(NRF-2, 
E4TF1-
60) 
transcription 
factor 
GABPα (GA binding protein a) is required to maintain a higher 
expression of IL-7Rα in memory precursor CD8 T upon LCMV 
infection 
alois mice after LCMV infection: ↑% IL-7Rαhi cells  
(Chandele 
et al., 2008) 
GFI1 transcription factor 
GFI1 (growth factor independence 1) is required to repress IL-7Rα 
transcription in CD8 effector T cells upon LCMV infection 
(Chandele 
et al., 2008) 
  
gfi-1 KO: neutrophenia, early lethality, ↓thymic cellularity but 
normal peripheral CD8 and CD4 T cells 
alois mice: no observed symptoms of disease or lethality, no 
change in thymic cellularity 
(Hock et al., 
2003) 
IL-2 inflammatory cytokine 
IL-2 upregulates expression of Eomes, Perforin, and IFNγ but 
downregulates expressionn of Bcl-6, IL-7Rα via STAT5 
il2 KO CD8 T cells after LCMV infection: 
↑Bcl-6 expression, ↓Perforin, GrB, KLRG1, T-bet expression on 
CTL, poor CTL killing ability 
alois mice: wild type levels of IL-7Rα expression 
after LCMV infection: ↑%KLRG-1 
(Pipkin et 
al., 2010) 
MBD2 transcriptional repressor 
Mbd2 KO: healthy, fertile, no sign of disease or lymphocyte 
developmental problem 
Mbd2 KO mice after LCMV infection: 
↓%IL-7Rαhi at day 8 and day 21 post-infection 
↑%CD44+ and KLRG-1+ on CTL at day 8 
alois mice: no observed symptom of diseases 
after LCMV infection: ↓%IL-7Rα, ↑KLRG-1 
(Kersh, 
2006) 
Table 15: A candidate gene list for alois mutation 
 
1. Growth factor independence (Gfi-1) and GA binding protein α (GABPα) 
Both Gfi-1 and GABPα null mutants present an aberrant myeloid cell differentiation. Gfi-1-/- 
mice lack mature neutrophils in the periphery and have increased populations of immature 
granulocytes and machrophages (Gr-1+Mac-1+) cells in the bone marrow (Hock et al., 2003). 
In the case of Gabpa-/- mice, the percentage of myeloid progenitor is greatly reduced and 
the levels of CD11b and Gr-1 expression in the bone marrow is low (Yang et al., 2011). Gfi-1 
and GABPα have been shown to control IL-7Rα expression in CTL upon viral infection: Gfi-1 
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represses IL-7Rα expression by antagonizing GABPα binding on the IL-7Rα promoter. This 
was discovered by adoptively transferring Gfi-1 and GABPα conditional knock-out CD8+ T 
cells which specifically recognise LCMV gp33 epitope into LCMV-infected congenic recipients 
(Chandele et al., 2008).   
In the case of alois, we also observe a reduction in IL-7Rα expression. It would therefore be 
tempting to speculate that alois affects GABPα or its functional partners. Unfortunately, we 
have not yet assessed the myeloid cell composition in the peripheral blood of alois mice, but 
we know that their peripheral lymphocyte distribution is normal (fig. 72). Changes in 
myeloid cell populations in alois mice could point to Gfi-1 and GABPα as good candidates. 
 
2. Methyl-CpG-binding domain (MBD)-containing proteins 2 (MBD2) 
MBD2, a component of MeCP1 complex, is a transcriptional repressor which recruits histone 
deacetylase on metylated DNA to actively induce gene silencing (Ng et al., 1999). Mbd2-/- 
mice are viable, fertile, without any known lymphocyte development problem or diseases 
(Hendrich et al., 2001). Upon LCMV infection, Mbd2-/- mice present an increased KLRG-1 and 
a decreased IL-7Rα expression without any significant change in gp33- and np396-specific 
CD8+ T cell population (Kersh, 2006). However, their memory population is not as functional 
as the one of wild type mice.  
Based on these phenotypes, Mbd2 is a strong candidate for alois. We are therefore currently 
sequencing Mbd2 in alois mutants.  
 
Conclusion 
 
The alois mutation causes the hyper-expansion of KLRG-1+ effector CD8+ T cells and a 
reduction in IL-7Rα expressing CD8+ memory T precursor cells upon LCMV Armstrong 
infection. The mutant mice do not present any visible health defects and their lymphocyte 
development does not seem to be disrupted. If this mutation is confirmed to be a novel 
mutation, alois mice will be a good model to study CD8+ T cell immune response upon 
infection.  
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General discussion 
 
In this project, we have successfully performed an ENU mutagenesis which has allowed us 
to isolate 3 mutant strains with distinctive phenotypes upon acute viral infection. Overall, 
we have produced 154 ENU injected males and screened 1263 G3 females for their immune 
responses to LCMV Armstrong infection. In this section, we will discuss these results.  
 
1. ENU mutagenesis and breeding 
1.1 ENU dose and mice survival and fertility 
Our mutagenesis was performed by injecting 3 weekly doses of 90mg of ENU/kg of body 
weight to C57BL/6J male mice. Originally, the dose we used was 100mg of ENU/kg of body 
weight based on the work done in the laboratory of M. Justice (Justice et al., 2000b). 
However, when using this high dose, we observed that most of the injected mice died in the 
few weeks after the last ENU injection (fig. 8), preventing us from getting enough G1 males 
for further breeding. It has been reported that there are some variations in survival and 
fertility rates among inbred strains and that C57BL/6J seems to be relatively susceptible to 
ENU injections as compared to other strains, such as C3HeB/Fe or Balb/c (Justice et al., 
2000b). The exact reason for strain-dependent susceptibility of ENU injection is not yet fully 
understood, but strain differences in their ability of efficiently deal with DNA repair has 
been considered as one reason. By transferring its alkyl group to nucleic acids, ENU 
produces high levels of DNA adducts (by-products) which will be used instead of proper 
nucleotides during DNA replication and eventually cause DNA mismatch (Justice et al., 1999). 
If a dose of ENU which exceeds the threshold for the DNA repairing machinery is applied, 
these ENU-induced adducts cannot be removed quickly enough and will induce toxicity 
(Favor, 1998). Therefore, inbred strains with a higher threshold can tolerate higher doses of 
ENU.  
 
Because of the susceptibility of our C57BL/6J mice to the high dose of ENU, we decided to 
reduce the ENU dose to 90mg/kg of body weight per injection. This resulted in a better 
survival rate and the mice recovered their fertility faster, providing enough G1 males for our 
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subsequent breeding. However, it has been reported that the decrease in ENU treatment 
would most probably have lowered the mutation rate in our mutagenesis (Justice et al., 
2000b). Even though this is true, our overall mutagenesis was not severely affected as we 
still could isolate mutants from our screen with a good mutant ratio. Therefore, lowering of 
ENU dose to 90mg/kg of body weight was beneficial for our project.  
 
1.2 Breeding scheme 
Our breeding scheme was designed to screen and isolate recessive mutations affecting the 
immune response to virus as most ENU-induced mutations are expressed as recessive traits 
(Rutschmann and Hoebe, 2008). However, we could have screened G1 mice for dominant 
mutations if our screening procedure did not take place in a containment level 3, as infected 
mice could not be used for further breeding.  
 
Our decision to use 2 G2 daughters per G1 father and to screen 3 G3 mice per G1 x G2 
parents was based on preliminary efficiency calculations. We could have used 3 G2 
daughters per G1 father or doubled the number of G3 mice screened per G1 x G2 pair. 
However, each of these changes only increase theoretical mutant estimation rate by 15% 
with a great increase in workload.  
 
To reduce standard deviation of screening parameters as much as possible, we only 
screened G3 female mice. However, by doing so, we lost the possibility to isolate sex 
chromosome-linked mutations. Because of our breeding scheme, any X-linked mutation 
occurring in the G0 male was not passed onto its G1 progeny. If a mutation was on the G0 Y 
chromosome, it would be passed onto males in the pedigree, but we could not isolate them 
as we decided to screen females.  
 
2. Screening procedure and isolation of phenodeviants 
To explain how memory cells differentiate from naive CD8+ T cells, several models have 
been proposed. In the early 1990s, it was suggested that the intensity of antigen stimulation 
decides CD8+ T cell fate, based on what was called the “decreasing-potential” model of 
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memory development. Weak and persistent antigen stimulation would lead precursors of 
CTL to become memory T cells while stronger antigen stimulation would result in CTL 
development (Ahmed and Gray, 1996). Later, Lanzavecchia and Sallusto built up this model 
to explain how Tem and Tcm develop (Lanzavecchia and Sallusto, 2000) and called their 
model the "progressive differentiation model". This model proposes that among naive CD8+ 
T cells which have the capacity to become memory cells, some of them will become Tem if 
they make slightly stronger contact with the antigen than the others which will become Tcm. 
However, if the fate of a naive CD8+ T cell was already decided at the first antigen encounter, 
a conversion of Tem to Tcm which was observed by Wherry et al. would not be able to be 
explained by this model (Wherry et al., 2003). Instead, the same authors proposed a "linear 
differentiation model" of memory T cells to explain this observation, in association with a 
previous report about the linear differentiation of CTL by Opferman et al. (Opferman et al., 
1999) (fig. 73, upper diagram). According to this model, the memory population derives 
directly from CTL which survived cell death after viral clearance to be Tem, whereas Tcm 
originate from Tem in the presence of IL-7. Yet, this model is not flawless as it would be 
tricky to explain the shift from Tcm to Tem observed by Unsoeld and Pircher, when they 
analysed the composition of the memory population formed by primary and secondary 
infections (Unsoeld and Pircher, 2005). 
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Figure 73: Models of memory T cell development 
The upper diagram depicts the concept of linear memory development model (Opferman et 
al., 1999) and the lower diagram shows a combined version of memory development based 
on the linear model (Kalia et al., 2006). The blue arrow indicates viral infection.  
 
Regardless of models, to become a memory cell, a CD8+ T cell has to survive from apoptosis 
and to enter quiescence. Our initial plan was to use a BrdU pulse-chase approach to 
distinguish memory precursors, assuming that the linear differentiation model was the most 
probable one (that antigen-primed CTL would survive through the contraction phase and 
remain quiescent to become memory precursors). However, while we were testing the 
correlation between BrdU and IL-7Rα, we realised that only 63% of IL-7Rα expressing CD8+ T 
cells retained high amount of BrdU (fig. 16). Since the upregulation of IL-7Rα is a hallmark of 
memory precursor cells (Kaech et al., 2002), if the linear model was true, the correlation 
would be nearly 100%. In addition, it has been reported that IL-7Rα+ memory cells are also 
directly generated from activated CD8+ T cells which had contact with antigens but did not 
undergo CTL expansion (Lanzavecchia and Sallusto, 2000). Moreover, it has been shown that 
even a cytokine (IL-2, IL-15) gradient can drive memory cell differentiation from antigen-
primed naive T cells without going through the CTL stage (Manjunath et al., 2001). These 
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results altogether imply that some of memory cells do not originated from CTL, suggesting a 
combined model of memory development (fig. 73, lower diagram).  
 
This combined model of memory formation suggests that memory T cells can be formed by 
two ways: they are from CTL which escaped contraction and from activated T cells which 
had weak antigen contact during the activation phase. The later cell population does not 
undergo the expansion phase, therefore, will not incorporate much BrdU upon pulse-chase 
experiment. Because of this reason, it seems that BrdU pulse-chase experiment is only good 
to indicate memory precursors generated from survived CTL from the contraction phase. 
Our data about IL-7Rα and BrdU correlation can be another supporting evidence for the 
combined model of memory development. Finally, by using IL-7Rα and KLRG-1 combination 
instead of BrdU, we could have a reliable qualitative information about Ag-TL population in 
our screening.  
 
To prevent isolating false positives and to isolate mutants with strong distinctive 
phenotypes, it was crucial for us to establish tight screening standards. First, we established 
that wild type and G3 mice had slightly different immune responses to LCMV infection in 
terms of the percentage of gp33+CD8+ cells and of KLRG-1 and IL-7Rα expression (table 5). 
This is probably due to the ENU mutagenesis having an effect on the genetic background of 
all G3 mice, affecting for example their general fitness. Therefore, for each week of 
screening, means and SD from G3 mice were used as internal controls. Individuals 
presenting outstanding values were considered phenodeviants.  
 
As a result, we have successfully isolated 3 mutant strains from 1263 G3 mice (table 6). 
When compared to other published papers on ENU mutagenesis, we have isolated an 
average number of mutants with our breeding and screening strategies (Crozat et al., 2007; 
Hoebe et al., 2003; Jun et al., 2003; Randall et al., 2009; Tabeta et al., 2006). For example, 
Crozat et al (Tabeta et al., 2006) have identified 8 mutants from a library of 3500 G3 mice 
from G1 x G2 back-cross, that is 1 mutant per 400~500 G3 mice. In addition, Randall et al 
(Randall et al., 2009) have identified 2 mutants from the screen of pedigrees from 301 G1. 
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Although our first mutant was isolated after screening more than 700 G3 mice, our overall 
mutant isolating rate was still in this range.  
 
3. Conclusion on our ENU mutagenesis approach 
We used a forward genetic approach based on ENU germline mutagenesis and isolated new 
genes which are involved in CD8 memory T cell formation and maintenance. In general, our 
mutagenesis was successful in terms of isolation efficiency and type of genes that we have 
isolated. However, due to the fact that our screening was performed in a containment level 
(CL) 3 facility, the speed at which we established homozygous strains was seriously affected. 
In the case of binu and alois, it took about a year to establish their first homozygous 
breeding pair. If we used a different antigen to induce CD8+ T cell immune response which 
does not require a CL3 facility, it would have taken much less time to have homozygous 
breeding pairs. In this case, we could also have screened G1 mice to isolate dominant 
mutations. 
 
Our mutants produced by random ENU mutagenesis enabled us to investigate the function 
of the affected genes. In case of memi, we first reported the altered expression of cell cycle 
regulators in DCK loss-of-function mutants. As DCK functionality has been known to be 
important for effective anti-cancer chemotherapy, for example, by gemcitabine, it can be 
used to improve the drug efficacy. In addition, memi mutation not only induces hyper-
proliferation, but also elevated cell death. If we could understand how a truncated DCK can 
eventually induce more apoptosis than wild type protein, we could use this knowledge to 
develop novel drugs which can be applied to patients with low DCK functionality. This 
animal model would be better than the knock-out model, as it would be closer to the real 
patients' clinical condition. For the other two mutants, binu and alois, once their affected 
genes have been identified, they will be useful to understand how CD8 memory develops 
after a viral infection. In addition, binu would be a valuable model to study development of 
Tcm and Tem and its altered response to LCMV epitopes. 
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Finally, to study genetic pathways required for any phenotype of interest, reverse genetic 
approaches based on chromosome engineering and gene knock-out techniques can be good 
alternative to ENU mutagenesis. Even though they require the construction of vectors and 
the continuous production of targeted mouse ES cell lines, they have a great advantage: the 
identity of the gene is known from the start (Guo et al., 2004). However, they never 
guarantee that a phenotype of interest will be found, which is the power of non-hypothesis 
driven approaches like forward genetics. In addition, ENU mutagenesis is also powerful 
especially when a single nucleotide change induces a dramatic phenotypical difference. For 
example, our memi mutant generated by ENU mutagenesis will be able to give a deeper 
insight of the importance of 14 amino acids at C-terminal end of DCK for its enzymatic 
activity. It would be difficult to discover the importance of these 14 amino acids by a 
targeted gene-knockout technique. Another example is the triple D (3D) mutation which is 
an ENU-induced missense mutation of Unc93b, the gene codes UNC-93B, a highly conserved 
endoplasmic recticulum protein (Tabeta et al., 2006). Due to the 3D mutation, TLR3, 7 and 9 
signalling defect is induced which enabled the researchers to find a novel role of UNC-93B in 
innate immune response. As revealed from several other large-scale ENU mutagenesis 
programme and our own project, forward genetics allows us to discover good candidate 
genes to understand human diseases and develop better treatments.  
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